Signify Health (SGFY) 10-Q 10 Nov 21 2021 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2021	Oct. 31, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-40028
Entity Registrant Name	Signify Health, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-3481223
Entity Address, Address Line One	800 Connecticut Avenue
Entity Address, City or Town	Norwalk
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06854
City Area Code	203
Local Phone Number	541-4600
Title of 12(b) Security	Class A common stock, par value $0.01 per Share
Trading Symbol	SGFY
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		170,420,536
Entity Central Index Key	0001828182
Amendment Flag	false
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 678.8	$ 72.6
Accounts receivable, net	169.2	270.6
Contract assets	94.6	27.8
Restricted cash	7.1	4.4
Prepaid expenses and other current assets	17.7	13.8
Total current assets	967.4	389.2
Property and equipment, net	23	25.4
Goodwill	597.1	596.7
Intangible assets, net	478.5	506.9
Deferred tax assets	48.3	0
Other assets	12.2	4.1
Total assets	2,126.5	1,522.3
Current liabilities
Accounts payable and accrued expenses	124.7	147.6
Contract liabilities	33.4	6.2
Current maturities of long-term debt	3.5	4.2
Contingent consideration	2.4	13.1
Deferred tax liability	0	1.9
Other current liabilities	10.3	16.6
Total current liabilities	174.3	189.6
Long-term debt	335.4	397.1
Contingent consideration	0	2.1
Customer EAR liability	80.4	21.6
Tax receivable agreement liability	59.6	0
Deferred tax liabilities	1.8	0
Other noncurrent liabilities	15.5	17.9
Total liabilities	667	628.3
Commitments and Contingencies
Members' equity	0	894
Additional paid-in capital	1,100.1
Accumulated deficit	(3)
Contingently redeemable noncontrolling interest	360.1
Total stockholders' equity	1,459.5	894
Total members' equity		894
Total liabilities and stockholders' / members' equity	2,126.5	$ 1,522.3
Class A Common Stock
Current liabilities
Common stock	1.7
Class B Common Stock
Current liabilities
Common stock	$ 0.6

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Members' equity	$ 0	$ 894
Class A Common Stock
Common stock par value (in dollars per share)	$ 0.01	$ 0.01
Common stock issued (in shares)	170,355,960	0
Common stock outstanding (in shares)	170,355,960	0
Class B Common Stock
Common stock par value (in dollars per share)	$ 0.01	$ 0.01
Common stock issued (in shares)	56,482,324	0
Common stock outstanding (in shares)	56,482,324	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Revenue		$ 199.2	$ 154.7	$ 592	$ 417.1
Operating expenses
Service expense (exclusive of depreciation and amortization shown below)		100.4	83.4	303	203.4
Selling, general and administrative expense (exclusive of depreciation and amortization, shown below)		65.8	50.4	188	148.5
Transaction-related expenses		2.9	6.8	9.5	10.8
Depreciation and amortization		17.6	15.8	51.6	46
Total operating expenses		186.7	156.4	552.1	408.7
Income (loss) from operations		12.5	(1.7)	39.9	8.4
Interest expense		4.2	5.1	17.5	16.2
Loss on extinguishment of debt		0	0	5	0
Other (income) expense		(27.4)	6.3	43.6	6.9
Other (income) expense, net		(23.2)	11.4	66.1	23.1
Income (loss) before income taxes		35.7	(13.1)	(26.2)	(14.7)
Income tax expense (benefit)		6.4	0.2	(3.7)	0.5
Net income (loss)		29.3	(13.3)	$ (22.5)	(15.2)
Net income (loss) attributable to parent		20.2	$ (13.3)		$ (15.2)
Net income (loss) attributable to noncontrolling interest		$ 9.1
Earnings (loss) per share of Class A common stock
Basic (in dollars per share)	[1]	$ 0.12		$ (0.02)
Diluted (in dollars per share)	[1]	$ 0.12		$ (0.02)
Weighted average shares of Class A common stock outstanding
Basic (in shares)	[1]	169,055,078		167,905,136
Diluted (in shares)	[1]	172,433,950		167,905,136
[1]	(1)Basic and diluted net loss per share of Class A common stock is applicable only for the periods subsequent to February 12, 2021, which is the period following the initial public offering ("IPO") and related Reorganization Transactions (as defined in Note 1 to the Unaudited Condensed Consolidated Financial Statements). See Note 15 for the basis for the computation of net earnings (loss) per share.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' / Members’ Equity - USD ($) $ in Millions	Total	Class A Common Stock	Class B Common Stock	Members' Equity	Common StockClass A Common Stock	Common StockClass B Common Stock	Additional paid-in capital	Non-controlling interest	Retained earnings (Accumulated deficit)
Beginning balance at Dec. 31, 2019				$ 957.6
Increase (Decrease) in Members' Equity [Roll Forward]
Repurchase of member units				(54)
Member distributions				(8.1)
Equity-based compensation				10
Proceeds from exercises of stock options				0.7
Tax refunds received on behalf of New Remedy Corp				1
Repurchase of stock on behalf of New Remedy Corp				(0.6)
Net loss	$ (15.2)			(15.2)
Ending balance at Sep. 30, 2020				891.4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Proceeds from exercises of stock options				0.7
Net income (loss)	(15.2)			(15.2)
Beginning balance at Jun. 30, 2020				964.3
Increase (Decrease) in Members' Equity [Roll Forward]
Repurchase of member units				(54)
Member distributions				(8.1)
Equity-based compensation				2.1
Proceeds from exercises of stock options				0.3
Tax refunds received on behalf of New Remedy Corp				0.1
Repurchase of stock on behalf of New Remedy Corp				0
Net loss	(13.3)			(13.3)
Ending balance at Sep. 30, 2020				891.4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Proceeds from exercises of stock options				0.3
Net income (loss)	(13.3)			(13.3)
Beginning balance at Dec. 31, 2020	894			894
Increase (Decrease) in Members' Equity [Roll Forward]
Net loss	(22.5)
Ending balance at Sep. 30, 2021				0
Beginning balance at Dec. 31, 2020	894				$ 0	$ 0	$ 0	$ 0	$ 0
Beginning balance (in shares) at Dec. 31, 2020		0	0		0	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exchange of LLC units (in shares)					1,748,451	1,748,451
Net income (loss)	(22.5)
Ending balance at Sep. 30, 2021	1,459.5				$ 1.7	$ 0.6	1,100.1	360.1	(3)
Ending balance (in shares) at Sep. 30, 2021		170,355,960	56,482,324		170,355,960	56,482,324
Increase (Decrease) in Members' Equity [Roll Forward]
Proceeds from exercises of stock options	2.2						2.2
Net loss	29.3							9.1	20.2
Ending balance at Sep. 30, 2021				$ 0
Beginning balance at Jun. 30, 2021	1,423.9				$ 1.7	$ 0.6	1,084.2	360.6	(23.2)
Beginning balance (in shares) at Jun. 30, 2021					168,023,155	57,911,222
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity-based compensation subsequent to Reorganization Transactions	3.9						2.4	1.5
Equity-based compensation subsequent to Reorganization Transactions (in shares)						319,553
Proceeds from exercises of stock options	2.2						2.2
Proceeds from exercises of stock options (in shares)					584,354
Tax payments on behalf of non-controlling interest	(0.2)							(0.2)
Exchange of LLC units							10.9	(10.9)
Exchange of LLC units (in shares)					1,748,451	(1,748,451)
Equity impact of tax receivable agreement liability and deferred taxes arising from LLC Interest ownership exchanges	0.4						0.4
Net income (loss)	29.3							9.1	20.2
Ending balance at Sep. 30, 2021	$ 1,459.5				$ 1.7	$ 0.6	$ 1,100.1	$ 360.1	$ (3)
Ending balance (in shares) at Sep. 30, 2021		170,355,960	56,482,324		170,355,960	56,482,324

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Operating activities
Net loss	$ (22.5)	$ (15.2)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	51.6	46
Equity-based compensation	9.7	10
Customer equity appreciation rights	14.8	7.5
Remeasurement of customer equity appreciation rights	44	6.9
Amortization of deferred financing fees	2	1.3
Loss on extinguishment of debt	5	0
Remeasurement of contingent consideration	2.2	0.2
Payment of contingent consideration	(1.9)	(1.8)
Deferred income taxes	(8.8)	0
Other	0	0.2
Changes in operating assets and liabilities:
Accounts receivable	101.4	25
Prepaid expenses and other current assets	(3.9)	(4.8)
Contract assets	(66.8)	(71.7)
Other assets	(0.2)	(0.2)
Accounts payable and accrued expenses	(22.2)	(11.5)
Contract liabilities	27.2	31.9
Other current liabilities	(6.3)	6.3
Other noncurrent liabilities	(1.9)	10.6
Net cash provided by operating activities	123.4	40.7
Investing activities
Capital expenditures - property and equipment	(3.7)	(13)
Capital expenditures - internal-use software development	(17.1)	(15.7)
Purchase of long-term investment	(5)	0
Business combinations, net of cash acquired	(0.4)	0
Net cash used in investing activities	(26.2)	(28.7)
Financing activities
Repayment of long-term debt	(412.5)	(2.1)
Proceeds from issuance of long-term debt	350	0
Repayment of borrowings under revolving credit facility	0	(15)
Proceeds from borrowings under revolving credit facility	0	92
Repayments of borrowings under financing agreement	(0.5)	(0.2)
Proceeds from borrowings under financing agreement	0	0.6
Payment of contingent consideration	(13.1)	(38.2)
Payment of debt issuance costs	(9.2)	0
Distributions to non-controlling interest members	(10.6)	(8.1)
Proceeds from IPO, net	604.8	0
Refunds of taxes on behalf of New Remedy Corp	0.1	1
Proceeds related to the issuance of common stock under stock plans	2.7	0.1
Net cash provided by financing activities	511.7	30.1
Increase in cash, cash equivalents and restricted cash	608.9	42.1
Cash, cash equivalents and restricted cash - beginning of period	77	50.2
Cash, cash equivalents and restricted cash - end of period	685.9	92.3
Supplemental disclosures of cash flow information
Cash paid for interest	16.2	14.9
Cash payments, net of refunds, for taxes	7.1	0.3
Noncash transactions
Capital expenditures not yet paid	1	0.2
Assumption of liabilities from New Remedy Corp	26	0
Items arising from LLC interest ownership exchanges:
Establishment of liabilities under tax receivable agreement	8.3	$ 0
Deferred tax asset	$ 8.7

Nature of Operations

Nature of Operations	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	Nature of Operations Signify Health, Inc. (referred to herein as “we”, “our”, “us”, “Signify Health” or the “Company”) was incorporated in the state of Delaware on October 1, 2020 and was formed for the purpose of completing an initial public offering (“IPO”) of its common stock and related reorganization transactions as described below. As a result of the reorganization transactions in February 2021, we control, and therefore consolidate the operations of Cure TopCo, LLC (“Cure TopCo”) and its direct and indirect subsidiaries. Cure TopCo is a Delaware limited liability company formed on November 3, 2017. Cure TopCo has adopted a holding company structure and is the indirect parent company of Signify Health, LLC (“Signify”), a Delaware limited liability company. Signify was formed on November 3, 2017. Operations are performed through our wholly-owned subsidiaries. We are a healthcare platform that leverages advanced analytics, technology and nationwide healthcare provider networks to create and power value-based payment programs. Our customers include health plans, governments, employers, health systems and physician groups. We operate in two segments of the value-based healthcare payment industry: payment models based on individual episodes of care, or the Episodes of Care Services segment, and in-home health evaluations (“IHE”), or the Home & Community Services segment. Payment models based on individual episodes of care organize or bundle payments for all, or a substantial portion of, services received by a patient in connection with an episode of care, such as a surgical procedure, particular condition or other reason for a hospital stay. IHEs are health evaluations performed by a clinician in the home to support payors’ participation in Medicare Advantage and other government-run managed care plans. Our solutions support value-based payment programs by aligning financial incentives around, and providing tools to health plans and healthcare organizations designed to assess and manage risk and identify actionable opportunities for improved patient outcomes, care coordination and cost-savings. Initial Public Offering On February 16, 2021, Signify Health closed an initial public offering (“IPO”) of 27,025,000 shares of its Class A common stock at a public offering price of $24 per share, which included 3,525,000 shares issued pursuant to the full exercise of the underwriters’ over-allotment option. Signify Health received gross proceeds of $648.6 million, which resulted in net cash proceeds of $609.7 million after deducting underwriting discounts and commissions of $38.9 million and before fees and expenses incurred in connection with the IPO and paid for by Cure TopCo. Signify Health used the proceeds to purchase newly-issued membership interests from Cure TopCo at a price per interest equal to the IPO price of its Class A common stock, net of the underwriting discount and commissions. Reorganization Transactions In connection with the IPO, Signify Health and Cure TopCo completed a series of transactions (“Reorganization Transactions”) including the following: • The limited liability company agreement of Cure TopCo was amended and restated to, among other things, convert all outstanding equity interests into one class of non-voting common units (the “LLC Units”) and appoint Signify Health as the sole managing member of Cure TopCo. • The certificate of incorporation of Signify Health was amended and restated to authorize the issuance of two classes of common stock: Class A common stock and Class B common stock (collectively, the “common stock”). Each share of common stock entitles its holder to one vote per share on all matters submitted to a vote of our stockholders. The Class B common stock is not entitled to economic interests in Signify Health. • The acquisition of LLC Units through (i) the contribution of LLC Units in exchange for Class A common stock by New Mountain Partners V (AIV-C), LP (the “IPO Contribution”) and (ii) the “Mergers,” in which certain entities treated as corporations for U.S. tax purposes that held LLC Units (individually, a “Blocker Company” and together, the “Blocker Companies”), each simultaneously merged with a merger subsidiary created by us (and survived such merger as a wholly-owned subsidiary of Signify Health), after which each Blocker Company immediately merged into Signify Health. • New Remedy Corp. merged with and into Signify Health. • Each Continuing Pre-IPO LLC Member (as defined below) was issued a number of shares of our Class B common stock in an amount equal to the number of LLC Units held by such Continuing Pre-IPO LLC Member at the time of the IPO, except in the case of Cure Aggregator (“Cure Aggregator”). Shares of Class B common stock were issued to the direct holders of common units in Cure Aggregator in proportion to their interests in Cure Aggregator. These shares will not be entitled to any voting rights until the common units of Cure Aggregator that correspond to the shares have vested. Following the completion of the Reorganization Transactions, Signify Health owned approximately 74.1% of the economic interest in Cure TopCo. The Pre-IPO Members who retain their equity ownership in Cure TopCo subsequent to the Reorganization Transactions (the “Continuing Pre-IPO LLC Members”) owned the remaining 25.9% economic interest in Cure TopCo.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Significant Accounting Policies	Significant Accounting Policies Basis of Presentation These Condensed Consolidated Financial Statements are unaudited and have been prepared by us in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and following the rules and regulations of the Securities and Exchange Commission (the “SEC”). The financial statements included in this report should be read in conjunction with the Company’s audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020. In our opinion, they reflect all adjustments, including normal recurring items, that are necessary to present fairly the results of interim periods. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted as permitted by such rules and regulations; however, we believe that the disclosures are adequate to make the information presented not misleading. Operating results for the periods presented herein are not necessarily indicative of the results that may be expected for future interim periods or the entire fiscal year. Our quarterly results of operations, including our revenue, income (loss) from operations, net income (loss) and cash flows, have varied and may vary significantly in the future; therefore, period-to-period comparisons of our results of operations may not be meaningful. Accordingly, our interim results should not be relied upon as an indication of future performance. For the periods subsequent to the Reorganization Transactions effective February 12, 2021, the Condensed Consolidated Financial Statements represent Signify Health and our consolidated subsidiaries, including Cure TopCo. For the periods prior to the Reorganization Transactions, the condensed consolidated financial statements represent Cure TopCo and its consolidated subsidiaries, see Note 1 Nature of Operations . Signify Health was formed for the purpose of the IPO, which was effective in February 2021 and had no activities of its own prior to such date. We are a holding company and our sole material asset is a controlling ownership interest in Cure TopCo. The Condensed Consolidated Financial Statements include the accounts and financial statements of our wholly-owned subsidiaries and variable interest entities (“VIE”s) where we are the primary beneficiary. Results of operations of VIEs are included from the dates we became the primary beneficiary. All intercompany balances and transactions have been eliminated in consolidation. We have two operating segments, Home & Community Services and Episodes of Care Services as described in Note 1 Nature of Operations . Use of Estimates The accompanying Condensed Consolidated Financial Statements have been prepared in conformity with GAAP, which requires management to make estimates and assumptions affecting the reported amounts in our Condensed Consolidated Financial Statements and accompanying notes. These estimates are based on information available as of the date of the Condensed Consolidated Financial Statements; therefore, actual results could differ from those estimates. The significant estimates underlying our Condensed Consolidated Financial Statements include revenue recognition; allowance for doubtful accounts; recoverability of long-lived assets, intangible assets and goodwill; loss contingencies; accounting for business combinations, including amounts assigned to definite and indefinite lived intangible assets and contingent consideration; and equity-based compensation. As of September 30, 2021, the impact of the COVID-19 pandemic continues to unfold particularly on our Episodes of Care Services segment due to the passage of time between episode initiation and the performance and subsequent recognition of revenue for our services; See Note 3 The COVID-19 Pandemic . As a result, many of our estimates and assumptions have required increased judgment and carry a higher degree of variability and volatility. As events continue to evolve and additional information becomes available, our estimates may change materially in the future. Comprehensive Income (Loss) We have not identified any incremental items that would be considered a component of comprehensive income (loss) and accordingly a statement of comprehensive income (loss) is not reflected in the Condensed Consolidated Financial Statements because net income (loss) and comprehensive income (loss) are the same. Restricted Cash Under our Master Agreement with the Centers for Medicare and Medicaid Services (“CMS”), we were required to place certain funds in escrow for the benefit of CMS. These amounts, known as a Secondary Repayment Source (“SRS”), were primarily based on the size of our participation in the legacy CMS Bundled Payments for Care Improvement (“BPCI”) program, the predecessor program of the Bundled Payments for Care Improvement - Advanced initiative (“BPCI-A”). These funds were available to CMS as a supplemental payment source if we failed to pay amounts owed to CMS. Under the agreement, the funds are returned to us 18 months after the conclusion of the effective period of the CMS Master Agreement, or when all financial obligations to CMS are fulfilled. As of September 30, 2021 and December 31, 2020, there were $0.5 million in the SRS account included in restricted cash on the Condensed Consolidated Balance Sheets related to BPCI-A. We also withhold a portion of shared savings to customers in a “holding pool” to cover any potential subsequent negative adjustments through CMS’s subsequent reconciliation true-up process. These funds are distributed to customers following the final true-up if there is no negative adjustment. These amounts represent consideration payable to the customer and therefore have reduced revenue in the period earned. The funds have been received by us from CMS and are held in a separate cash account, included as restricted cash on the Condensed Consolidated Balance Sheets. Since the funds are payable to the customer at the point the final CMS true-up is made or a negative adjustment is due to us, the amounts are also included in accounts payable and accrued expenses on the Condensed Consolidated Balance Sheets. As of September 30, 2021 and December 31, 2020, there was $6.6 million and $3.5 million of restricted cash in the holding pool, respectively. As of December 31, 2020, we held $0.4 million of restricted cash, acquired as part of the PatientBlox acquisition. During the second quarter of 2021, in connection with the successful completion of the first earn out milestone outlined in the acquisition agreement, the balance of the restricted cash was released and paid to the sellers. As a result, there is no remaining balance of restricted cash related to the PatientBlox acquisition as of September 30, 2021. The following table reconciles cash, cash equivalents, and restricted cash per the Condensed Consolidated Statements of Cash Flows to the Condensed Consolidated Balance Sheets: September 30, December 31, 2021 2020 (in millions) Cash and cash equivalents $ 678.8 $ 72.6 Restricted cash 7.1 4.4 Total cash, cash equivalents, and restricted cash $ 685.9 $ 77.0 Accounts Receivable Accounts receivable primarily consist of amounts due from customers and CMS and are stated at their net realizable value. Management evaluates all accounts periodically and an allowance is established based on the latest information available to management. Management considers historical realization data, accounts receivable aging trends and other operational trends to estimate the collectability of receivables. After all reasonable attempts to collect a receivable have been exhausted, the receivable is written off against the allowance for doubtful accounts. As of September 30, 2021 and December 31, 2020, we had an allowance for doubtful accounts of $7.8 million and $5.1 million, respectively. Advertising and Marketing Costs Advertising and marketing costs are included in SG&A expenses and are expensed as incurred. Advertising and marketing costs totaled $0.4 million and $0.1 million for the three months ended September 30, 2021 and 2020, respectively, and $0.9 million and $1.2 million for the nine months ended September 30, 2021 and 2020, respectively. Income Taxes We are organized as a C Corporation and own a controlling interest in Cure TopCo which is organized as a partnership for tax purposes. For partnership and disregarded entities, taxable income and the resulting liabilities are allocated among the owners of the entities and reported on the tax filings for those owners. We record income tax (benefit) expense, deferred tax assets, and deferred tax liabilities only for the items for which we are responsible for making payments directly to the relevant tax authority. Deferred income taxes reflect the net tax effects of temporary differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws expected to be in effect when such differences are expected to reverse. Such temporary differences are reflected as deferred tax assets and deferred tax liabilities on the Condensed Consolidated Balance Sheets. A deferred tax asset is recognized if it is more likely than not that a tax benefit will be realized. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some or all of the deferred tax assets will be realized and, when necessary, a valuation allowance is established. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences become deductible. We may recognize tax liabilities when, despite our belief that our tax return positions are supportable, we believe that certain positions may not be fully sustained upon review by the tax authorities. Benefits from tax positions are measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon settlement. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences impact income tax expense in the period such determination is made. We recognize interest and penalties related to income taxes as a component of income tax expense. Recent Accounting Pronouncements Recently Adopted In June 2018, the FASB issued Accounting Standards Update No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”) . The amendments in ASU 2018-07 expanded the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 is effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. We elected to early adopt this new guidance for interim periods in 2020 with no significant impact to our financial statements. In November 2019, the FASB issued ASU 2019-08, Compensation – Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Codification Improvements – Share-Based Consideration Payable to a Customer (“ASU 2019-08”). ASU 2019-08 requires that an entity measure and classify share-based payment awards granted to a customer by applying the guidance in Topic 718. The amount recorded as a reduction of the transaction price is required to be measured on the basis of the grant-date fair value of the share-based payment award in accordance with Topic 718. The grant date is the date at which a grantor (supplier) and a grantee (customer) reach a mutual understanding of the key terms and conditions of a share-based payment award. ASU 2019-08 is effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. We elected to early adopt this new guidance for interim periods in 2020, which had an impact on the customer Equity Appreciation Rights (“EAR”) agreements. The initial grant date fair value of the EAR agreements is being recorded as a reduction of the transaction price beginning in 2020. See Note 17 Commitments and Contingencies . Pending Adoption We are an “emerging growth company” under the Jumpstart Our Business Startups Act (“JOBS Act”). Pursuant to the JOBS Act, an emerging growth company is provided the option to adopt new or revised accounting standards that may be issued by FASB or the SEC either (i) within the same periods as those otherwise applicable to non-emerging growth companies or (ii) within the same time periods as private companies. We intend to take advantage of the exemption for complying with new or revised accounting standards within the same time periods as private companies. The effective dates below are the effective dates we expect to adopt the new accounting pronouncements, which are those permitted for a company that is not an issuer. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) which requires lessees to recognize leases on the balance sheet by recording a right-of-use asset and lease liability. This guidance is effective for non-public entities for annual reporting period s beginning after December 15, 2021. Early adoption is permitted. During 2021, we have formed a cross-functional adoption project team and continue to make progress as we plan to adopt this new guidance as of January 1, 2022 and will apply the transition option, whereby prior comparative periods will not be retrospectively presented in the consolidated financial statements. We expect to elect the package of practical expedients not to reassess prior conclusions related to contracts containing leases, lease classification and initial direct costs and the lessee practical expedient to combine lease and non-lease components for all asset classes. We expect to make a policy election to not recognize right-of-use assets and lease liabilities for short-term leases for all asset classes. We continue to evaluate other practical expedients available under the guidance. We are also assessing the impact to our accounting policies, processes, disclosures, and internal control over financial reporting. The cross-functional project team is evaluating our portfolio of leases, which primarily consist of real estate leases, as well as the system, process and policy change requirements needed to implement. We have made progress in gathering the necessary data elements for the complete lease population and a lease accounting system has been selected, with system configuration and implementation underway. We expect to record a right of use asset and corresponding lease liability for all outstanding leases and it is likely that the adoption and recognition of these assets and liabilities will have a material impact to our Condensed Consolidated Balance Sheet given the number of facility leases we currently have. We continue to evaluate the expected impact to our Condensed Consolidated Statements of Operations and Cash Flows. In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326) (“ASU 2016-13”) which introduced the current expected credit losses methodology for estimating allowances for credit losses. ASU 2016-13 applies to all financial instruments carried at amortized cost and off-balance-sheet credit exposures not accounted for as insurance, including loan commitments, standby letters of credit, and financial guarantees. The new accounting standard does not apply to trading assets, loans held for sale, financial assets for which the fair value option has been elected, or loans and receivables between entities under common control. ASU 2016-13 is effective for non-public entities for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. We are evaluating the impact of this new guidance on our financial statements.

The COVID-19 Pandemic

The COVID-19 Pandemic	9 Months Ended
	Sep. 30, 2021
Unusual or Infrequent Items, or Both [Abstract]
The COVID-19 Pandemic	The COVID-19 PandemicOur operations in our Home & Community Services segment were significantly affected by the COVID-19 pandemic early in 2020 as we temporarily paused IHEs in March 2020 and shortly thereafter expanded our business model to perform virtual IHEs (“vIHEs”) in order to make up for some of the lost IHE volume. We resumed in-person IHE visits beginning in July 2020. Despite the availability of vIHEs, many of our customers had preferred to postpone in-person IHEs to the second half of 2020. Overall we saw significant incremental in-person IHE volume in the second half of 2020, particularly in the fourth quarter, related to this catch-up and additionally as certain customers increased the overall volumes they placed with us. In order to meet this volume growth, we onboarded additional providers into our network which resulted in proportionally higher expenses. In 2021, the vast majority of our evaluations have been in-person IHEs, although we continue to perform vIHEs. O verall, IHE volume has been strong in the first nine months of 2021 indicating the direct impact of COVID-19 on the Home & Community Services segment has subsided considerably. During the remainder of 2021, we expect seasonality trends in our Home & Community Services segment to be more consistent with historical trends which have typically seen a lower number of IHEs performed in the fourth quarter. Our Episodes of Care Services segment has also been negatively impacted by the pandemic. At certain times during the pandemic, governmental authorities recommended, and in certain cases required, that elective, specialty and other procedures and appointments, including certain acute and post-acute care services, be suspended or canceled to avoid non-essential patient exposure to medical environments and potential infection with the virus that causes COVID-19. In addition, the temporary suspension or cancellation of services was put in place to focus limited resources and personnel capacity toward the prevention of, and care for patients with, COVID-19. This resulted in fewer elective procedures and a general reduction in individuals seeking medical care starting at the end of the first quarter of 2020, which contributed to a substantially lower number of episodes being managed in 2020. Due to the nature of the BPCI-A program, however, there is a significant lag between when the episodes are initiated and when CMS reconciles those services and we recognize revenue over a 13 month period encompassing both of those points in time. As such, there was no immediate impact to our revenues in early 2020 as we were still recognizing revenue from pre-COVID 19 performance. However, the specific impact of those lower volumes on our program size and revenues was more evident later in 2020 as evidenced by our 2020 annual weighted average program size, and as described below, the impact of lower volumes carried forward into 2021. In the third quarter of 2020 and in response to the COVID-19 pandemic, CMS announced that healthcare providers could either (i) continue in the BPCI-A program with no change or (ii) as an exception to the previous rules of the program, healthcare providers could choose between the following two options for 2020: • eliminate upside and downside risk by excluding all episodes from reconciliation; or • exclude from reconciliation those episodes with a COVID-19 diagnosis during the episode. Healthcare providers made their elections by September 25, 2020. The results of those elections reduced the total number of episodes we managed during 2020 and also for 2021 and, therefore, reduced program size. While these provider elections temporarily reduced program size in the near term, this impact was at least initially partially offset by a higher savings rate achieved due to a combination of improved performance by some of our partners as well as certain partners that were underperforming choosing to exclude some or all of their episodes from reconciliation in 2020. Subsequently, CMS announced that all episodes in 2021 with a COVID-19 diagnosis would be automatically excluded from reconciliation, which further reduced program size for all of 2021. The reconciliation results received from CMS during the second quarter of 2021 negatively impacted our savings rate as it provided incremental information on the impact of COVID-19. This was driven primarily by the following factors: • missing comorbidity diagnosis codes that did not properly reflect patient acuity, thereby impacting patient case mix adjustments and reducing episode pricing. There is a 90-day period prior to an acute episode being triggered that CMS incorporates for diagnoses coding which ultimately adjusts an episode’s target pricing. During the pandemic, Medicare patients were avoiding routine healthcare visits and, as a result, comorbidities were not being diagnosed and coded and • patients being discharged during the pandemic from an acute care facility to inpatient rehabilitation facilities and other high-cost next sites of care when lower-cost skilled nursing facilities were facing COVID-19 outbreaks and staffing shortages. Due to the timing of revenue recognition between the time episodes are initiated and the confirmation and reconciliation of results by CMS, we would expect the above factors to have a continued impact in the near-term. Due to the passage of time between when we perform our services and the confirmation of results and subsequent cash settlement by CMS, COVID-19 did not have an impact on the cash we received from CMS during 2020 as the payments we received in 2020 related to pre-COVID-19 performance. The cash received from CMS in the first

Variable Interest Entities

Variable Interest Entities	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities	Variable Interest Entities We consolidate our affiliates when we are the primary beneficiary. The primary beneficiary of a VIE is the party that has both the decision-making authority to direct the activities that most significantly impact the VIE’s economic performance and the right to absorb losses or receive benefits that could potentially be significant to the VIE. Consolidated VIEs at September 30, 2021 and December 31, 2020 include seven and one physician practices, respectively, that require an individual physician to legally own the equity interests as certain state laws and regulations prohibit non-physician owned business entities from practicing medicine or employing licensed healthcare providers. We have determined we are the primary beneficiary of these VIEs as we have the obligation to absorb the losses from and direct activities of these operations. As a result, these VIEs are consolidated and any non-controlling interest is not presented. Recourse of creditors to these VIEs is limited to the assets of the VIE entities, which total $18.0 million and $1.8 million at September 30, 2021 and December 31, 2020, respectively. The carrying amount and classification of the VIEs’ assets and liabilities included in the Condensed Consolidated Balance Sheets, net of intercompany amounts, are as follows: September 30, December 31, 2021 2020 (in millions) ASSETS Current assets Cash and cash equivalents $ 3.7 $ 1.8 Accounts receivable, net 14.3 — Total current assets 18.0 1.8 Total assets $ 18.0 $ 1.8 LIABILITIES AND EQUITY Current liabilities Accounts payable and accrued expenses $ 0.3 $ 0.1 Total current liabilities 0.3 0.1 Total liabilities 0.3 0.1 Company capital 18.8 (0.7) Retained earnings (accumulated deficit) (1.1) 2.4 Total equity 17.7 1.7 Total liabilities and equity $ 18.0 $ 1.8

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Disaggregation of Revenue We earn revenue from our two operating segments, Home & Community Services and Episodes of Care Services, under contracts that contain various fee structures. Through our Home & Community Services segment, we offer health evaluations performed either within the patient’s home, virtually or at a healthcare provider facility, primarily to Medicare Advantage health plans (and to some extent, Medicaid). Additionally, we offer certain diagnostic screening and other ancillary services, and through our Signify Community solution, we offer services to address healthcare concerns related to social determinants of health. Through our Episodes of Care Services segment, we primarily provide services designed to improve the quality and efficiency of healthcare delivery by developing and managing episodic payment programs in partnership with healthcare providers, primarily under the BPCI-A program with CMS. Additionally, we provide certain complex care management services. All of our revenue is generated in the United States. We are dependent on a concentrated number of payors and provider partners with whom we contract to provide our services, S ee Note 20 Concentrations . The following table summarizes disaggregated revenue from contracts with customers by source of revenue, which we believe best presents the nature, amount and timing of revenue. Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 (in millions) (in millions) Evaluations $ 167.1 $ 112.5 $ 490.6 $ 294.9 Other 2.0 2.2 6.3 6.9 Home & Community Services Total Revenue 169.1 114.7 496.9 301.8 Episodes 27.8 37.5 88.5 107.2 Other 2.3 2.5 6.6 8.1 Episodes of Care Services Total Revenue 30.1 40.0 95.1 115.3 Consolidated Revenue Total $ 199.2 $ 154.7 $ 592.0 $ 417.1 Related Balance Sheet Accounts The following table provides information about accounts included on the Condensed Consolidated Balance Sheet. September 30, 2021 December 31, 2020 Episodes of Care Services Home & Community Services Total Episodes of Care Services Home & Community Services Total (in millions) Assets Accounts receivable, net (1) $ 33.2 $ 136.0 $ 169.2 $ 183.3 $ 87.3 $ 270.6 Contract assets (2) $ 94.6 $ — $ 94.6 $ 27.8 $ — $ 27.8 Liabilities Shared savings payable (3) $ 43.5 $ — $ 43.5 $ 80.8 $ — $ 80.8 Contract liabilities (4) $ 29.2 $ 4.2 $ 33.4 $ 4.8 $ 1.4 $ 6.2 Deferred revenue (5) $ 0.1 $ 0.9 $ 1.0 $ 2.4 $ 1.4 $ 3.8 (1) Accounts receivable, net for Episodes of Care Services included $4.6 million due from CMS as of September 30, 2021 primarily related to the fourth reconciliation period of the BPCI-A program and reflects a lower program size when compared to December 31, 2020. The remaining amount of accounts receivable for both Episodes of Care Services and Home & Community Services represent amounts to be received from customers. Home & Community Services accounts receivable as of September 30, 2021 reflects strong IHE volume in the third quarter and a return to a higher mix of in-person IHEs compared to vIHEs. (2) Contract assets represent management’s estimate of amounts we expect to receive under the BPCI-A program related to the next two reconciliation periods. As of September 30, 2021, contract assets cover episodes of care commencing in the period October 2020 through September 2021. Estimates for program size and savings rate are based on information available as of the date of the financial statements. We record an estimate of revenue related to these performance obligations over the 13-month period starting in the period the related episodes of care commence and through the estimated receipt of the semi-annual CMS reconciliation file. Any changes to these estimates based on new information will be recorded in the period such information is received. Total savings generated and revenue earned for the episodes of care in which a component of the contract asset recorded as of September 30, 2021 relates to, will be included in the semi-annual reconciliation expected from CMS during the fourth quarter of 2021. (3) Total shared savings payable is included in accounts payable and accrued expenses on the Condensed Consolidated Balance Sheets. Shared savings payable for Episodes of Care Services included $0.3 million due to CMS as of September 30, 2021, which we expect to settle with CMS during the next semi-annual reconciliation period in the fourth quarter of 2021. Shared savings payable for Episodes of Care Services included $6.8 million due to CMS as of December 31, 2020, the majority of which was settled with CMS in the first quarter of 2021. Shared savings payable included $36.6 million as of September 30, 2021 primarily related to the fourth reconciliation received in June 2021, which is expected to be paid to customers related to their portion of savings earned under the BPCI-A program. Additionally, there is $6.6 million included in shared savings payable at September 30, 2021, which represents amounts withheld from customers under the BPCI-A program based on contractual withholding percentages. This amount has been received by us from CMS and is held as restricted cash. We expect to remit these amounts to customers at the conclusion of the program, at which time both restricted cash and the liability will be reduced. (4) Contract liabilities in our Episodes of Care Services segment represent management’s estimate of savings amounts we expect to share with our customers based on contractual shared savings percentages related to the amounts we expect to be entitled to receive under the BPCI-A program for the next two reconciliation periods and service level agreements with certain customers. As of September 30, 2021, contract liabilities of $29.2 million cover episodes of care commencing in the period October 2020 through September 2021. These amounts offset the gross amount we expect to receive for the same period included in contract assets as of September 30, 2021. Contract liabilities in the Home & Community Services segment of $4.2 million as of September 30, 2021 represent management’s estimate of potential refund liabilities due to certain clients as a result of certain service levels not being achieved during the contractual periods primarily due to COVID-19. (5) Deferred revenue is included in other current liabilities on the Condensed Consolidated Balance Sheets and primarily relates to advance payments received from certain customers. The table below summarizes the activity recorded in the contract asset and liability accounts for the three and nine months ended September 30, 2021 and 2020. Three months ended September 30, Nine months ended September 30, Contract Assets 2021 2020 2021 2020 (in millions) (in millions) Balance at beginning of period $ 58.2 $ 50.9 $ 27.8 $ 38.3 Performance obligation completed, converted to accounts receivable — — (27.4) (43.9) Estimated revenue recognized related to performance obligations satisfied over time 36.4 59.1 94.2 115.6 Balance at end of period $ 94.6 $ 110.0 $ 94.6 $ 110.0 Three months ended September 30, Nine months ended September 30, Contract Liabilities 2021 2020 2021 2020 (in millions) (in millions) Balance at beginning of period $ 19.5 $ 8.3 $ 6.2 $ 3.1 Performance obligation completed, converted to shared savings payable — — (4.4) (4.6) Payments made to customer (0.1) — (0.7) — Estimated amounts due to customer related to performance obligations satisfied at a point-in-time 1.4 — 3.6 — Estimated amounts due to customer related to performance obligations satisfied over time 12.6 26.7 28.7 36.5 Balance at end of period $ 33.4 $ 35.0 $ 33.4 $ 35.0 Three months ended September 30, Nine months ended September 30, Deferred Revenue 2021 2020 2021 2020 (in millions) (in millions) Balance at beginning of period $ 4.4 $ 1.5 $ 3.8 $ 1.2 Payments received from customers 0.8 8.1 9.1 10.1 Revenue recognized upon completion of performance obligation (4.2) (3.5) (11.9) (5.2) Balance at end of period $ 1.0 $ 6.1 $ 1.0 $ 6.1 Three months ended September 30, Nine months ended September 30, Shared Savings Payable 2021 2020 2021 2020 (in millions) (in millions) Balance at beginning of period $ 54.2 $ 51.6 $ 80.8 $ 58.2 Amounts paid to customer and/or CMS (33.9) (26.7) (148.9) (94.6) Amounts due to customer upon completion of performance obligation 23.2 8.3 111.6 69.6 Balance at end of period $ 43.5 $ 33.2 $ 43.5 $ 33.2

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment, net were as follows as of each of the dates presented: September 30, 2021 December 31, 2020 (in millions) Computer equipment $ 19.1 $ 16.6 Leasehold Improvements 18.5 18.5 Furniture and fixtures 6.3 5.8 Software 2.5 2.4 Projects in progress 0.8 0.3 Property and equipment, gross 47.2 43.6 Less: Accumulated depreciation and amortization (24.2) (18.2) Property and equipment, net $ 23.0 $ 25.4

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets Intangible assets were as follows as of each of the dates presented: September 30, 2021 December 31, 2020 Estimated Useful Life (years) Gross Carrying Amount Accumulated amortization Net Carrying Value Gross Carrying Amount Accumulated amortization Net Carrying Value (in millions) Customer relationships 3 - 20 $ 530.5 $ (120.1) $ 410.4 $ 530.5 $ (92.9) $ 437.6 Acquired and capitalized software 3 - 6 140.7 (72.6) 68.1 123.6 (54.3) 69.3 Total $ 671.2 $ (192.7) $ 478.5 $ 654.1 $ (147.2) $ 506.9 We capitalized $5.5 million and $5.5 million for the three months ended September 30, 2021 and 2020, respectively, and $17.1 million and $15.7 million for the nine months ended September 30, 2021 and 2020, respectively, of internally-developed software costs. There was no impairment of intangible assets for the three or nine months ended September 30, 2021 and 2020. Amortization expense for intangible assets, inclusive of amounts subsequently written off from accumulated amortization, was $15.5 million and $14.0 million for the three months ended September 30, 2021 and 2020, respectively, and $45.4 million and $40.5 million for the nine months ended September 30, 2021 and 2020, respectively. Expected amortization expense as of September 30, 2021 related to intangible assets, including internal-use software development costs, was as follows: (in millions) Remainder of 2021 $ 15.7 2022 57.2 2023 52.6 2024 37.3 2025 33.9 thereafter 281.8 $ 478.5

Goodwill

Goodwill	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill The change in the carrying amount of goodwill for each reporting unit is as follows: Home & Community Services Episodes of Care Services Total (in millions) Balance at December 31, 2020 $ 170.4 $ 426.3 $ 596.7 Measurement period adjustments — 0.4 0.4 Balance at September 30, 2021 $ 170.4 $ 426.7 $ 597.1 There was no impairment related to goodwill during the three or nine months ended September 30, 2021 or 2020.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	9 Months Ended
	Sep. 30, 2021
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consist of the following: September 30, December 31, 2021 2020 (in millions) Accrued payroll and payroll-related expenses $ 46.4 $ 47.1 Shared savings payable 43.5 80.8 Other accrued expenses 28.1 19.0 Accounts payable 6.4 0.7 Accrued income taxes 0.3 — Total accounts payable and accrued liabilities $ 124.7 $ 147.6

Long-Term Debt

Long-Term Debt	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Long-term Debt	Long-Term Debt Long-term debt was as follows: September 30, December 31, 2021 2020 (in millions) Revolving Facility $ — $ — Term Loan — 272.5 2020 Incremental Term Loans — 140.0 2021 Term Loan 350.0 — Total debt 350.0 412.5 Unamortized debt issuance costs (6.3) (5.5) Unamortized discount on debt (4.8) (5.7) Total debt, net 338.9 401.3 Less current maturities (3.5) (4.2) Total long-term debt $ 335.4 $ 397.1 As of September 30, 2021 and December 31, 2020, the effective interest rate on Term Loan borrowings was 3.75% and 5.50%, respectively. As of December 31, 2020, the effective interest rate on the 2020 Incremental Term Loans was 6.25%. In June 2021, we refinanced the previously existing credit facility and entered into a new credit agreement (the “2021 Credit Agreement”) with a secured lender syndicate, which, among other things, reduced our total debt outstanding, lowered the interest rate, increased our borrowing capacity under the revolving facility and extended the maturity. The 2021 Credit Agreement includes a term loan of $350.0 million (the “2021 Term Loan”) and a revolving credit facility (the “Revolving Facility”) with a $185.0 million borrowing capacity. We are required to make amortization payments of 0.25% of the aggregate principal amount of the 2021 Term Loan on a quarterly basis, beginning in December 2021. The maturity date of the 2021 Term Loan is June 22, 2028 and the maturity date of the Revolving Facility is June 22, 2026. In connection with the refinancing, we recorded a loss on extinguishment of debt primarily related to the write-off of unamortized debt issuance costs of $5.0 million in our Consolidated Statement of Operations for the nine months ended September 30, 2021. There was no loss on extinguishment of debt for the three months ended September 30, 2021. The Credit Agreement is secured by substantially all of the assets of Signify and its subsidiaries. Similar to the previous credit agreement, the 2021 Credit Agreement contains customary representations and warranties as well as customary affirmative and negative covenants and events of default. Negative covenants include, among others (and in each case subject to certain exceptions), limitations on incurrence of liens by Signify and its restricted subsidiaries, limitations on incurrence of indebtedness by Signify and its restricted subsidiaries, limitations on making dividends and other distributions, limitations on engaging in asset sales, limitation on making investments, limitations on engaging in transactions with affiliates, and a requirement that the consolidated first lien net leverage ratio (as defined in the 2021 Credit Agreement) as of the end of any fiscal quarter is not greater than 4.50 to 1.00 if on the last day of such fiscal quarter the revolving credit loans and letters of credit outstanding exceeds 35% of the total amount of revolving credit commitments at such time. As of September 30, 2021, we were in compliance with all financial covenants. In March 2020, we borrowed $77.0 million under the prior revolving facility as a precautionary measure to ensure adequate liquidity as a result of the potential risks associated with COVID-19. We repaid this amount in November 2020. We currently have no borrowings outstanding under the Revolving Facility. As of September 30, 2021, we had $172.8 million available borrowing capacity under the Revolving Facility, as the borrowing capacity is reduced by outstanding letters of credit. The aggregate principal maturities of long-term debt due subsequent to September 30, 2021 are as follows: (in millions) Remainder of 2021 $ 0.9 2022 3.5 2023 3.5 2024 3.5 2025 3.5 Thereafter 335.1 $ 350.0

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Assets and liabilities measured at fair value on a recurring basis were as follows: September 30, 2021 Balance Sheet Classification Type of Instrument Level 1 Level 2 Level 3 Total (in millions) Cash equivalents Money market funds $ 400.1 $ — $ — $ 400.1 Customer EAR liability Customer equity appreciation rights — — 80.4 80.4 Contingent consideration Consideration due to sellers — — 2.4 2.4 December 31, 2020 Balance Sheet Classification Type of Instrument Level 1 Level 2 Level 3 Total (in millions) Cash equivalents Money market funds $ 20.0 $ — $ — $ 20.0 Customer EAR liability Customer equity appreciation rights — — 21.6 21.6 Contingent consideration Consideration due to sellers — — 15.2 15.2 There were no transfers between Level 1 and Level 2, or into or out of Level 3, during the three and nine months ended September 30, 2021 and 2020. The changes in Level 3 liabilities measured at fair value on a recurring basis were as follows: Contingent Consideration Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 (in millions) (in millions) Beginning of period $ 2.4 $ 40.0 $ 15.2 $ 39.8 Payment of contingent consideration — (40.0) (15.0) (40.0) Remeasurement of contingent consideration included in selling, general and administrative expense — — 2.2 0.2 Balance at September 30, $ 2.4 $ — $ 2.4 $ — Customer equity appreciation rights Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 (in millions) (in millions) Beginning of period $ 102.7 $ 3.2 $ 21.6 $ — Grant date fair value estimate recorded as reduction to revenue 5.0 4.9 14.8 7.5 Remeasurement of fair value included in other expense (income), net (27.3) 6.3 44.0 6.9 Balance at September 30, $ 80.4 $ 14.4 $ 80.4 $ 14.4 The valuation techniques and significant unobservable inputs used in recurring Level 3 fair value measurements were as follows as of September 30, 2021: Fair Value (in millions) Valuation Technique Significant Unobservable Inputs Assumption Customer equity appreciation rights $ 80.4 Monte Carlo Volatility 45.0% Dividend yield 0% Risk-free rate 0.53% Expected term (years) 3 Fair Value Valuation Technique Significant Unobservable Inputs Discount Rate Consideration due to sellers $ 2.4 Discounted approach Discount Rate 5.0% The valuation techniques and significant unobservable inputs used in recurring Level 3 fair value measurements were as follows as of December 31, 2020: Fair Value (in millions) Valuation Technique Significant Unobservable Inputs Assumption Customer equity appreciation rights $ 21.6 Monte Carlo Volatility 55.0% Dividend yield 0% Risk-free rate 0.11% Expected term (years) 1.35 Fair Value Valuation Technique Significant Unobservable Inputs Discount Rate Consideration due to sellers $ 15.2 Discounted approach Discount Rate 5.0% The fair value of our debt is measured at Level 3 and is determined based on fluctuations in current interest rates, the trends in market yields of debt instruments with similar credit ratings, general economic conditions and other quantitative and qualitative factors. The carrying value of our debt approximates its fair value as it is variable-rate debt. The carrying amounts of accounts receivable and accounts payable approximate their fair value because of the relatively short-term maturity of these instruments.

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Shareholders' Equity	Shareholders’ Equity See Note 1 Nature of Operations for details of the Reorganization Transactions effective in February 2021 in connection with our IPO. Initial Public Offering On February 16, 2021, Signify Health closed an IPO of 27,025,000 shares of its Class A common stock at a public offering price of $24 per share, which included 3,525,000 shares issued pursuant to the full exercise of the underwriters’ over-allotment option. Signify Health received gross proceeds of $648.6 million, which resulted in net cash proceeds of $609.7 million after deducting underwriting discounts and commissions of $38.9 million and before fees and expenses incurred in connection with the IPO incurred and paid for by Cure TopCo. Signify Health used the proceeds to purchase newly-issued membership interests from Cure TopCo at a price per interest equal to the IPO price of its Class A common stock, net of the underwriting discount and commissions. Amendment and Restatement of Certificate of Incorporation In connection with the Reorganization Transactions and IPO, our certificate of incorporation was amended and restated to, among other things, authorize the issuance of two classes of common stock: Class A common stock and Class B common stock. Class A Common Stock Holders of shares of Class A common stock are entitled to one vote for each share held of record on all matters on which stockholders are entitled to vote generally, including the election or removal of directors. The holders of Class A common stock do not have cumulative voting rights in the election of directors. Holders of shares of Class A common stock are entitled to receive dividends when and if declared by the board of directors out of funds legally available, subject to any statutory or contractual restrictions on the payment of dividends and to any restrictions on the payment of dividends imposed by the terms of any outstanding preferred stock. Upon liquidation, dissolution or winding up and after payment in full of all amounts required to be paid to creditors and to the holders of preferred stock having liquidation preferences, if any, the holders of shares of Class A common stock will be entitled to receive pro rata our remaining assets available for distribution. All shares of Class A common stock outstanding are fully paid and non-assessable. The Class A common stock are not subject to further calls or assessments. The rights, powers and privileges of Class A common stock are subject to those of the holders of any shares of preferred stock. Class B Common Stock Each share of Class B common stock entitles its holder to one vote per share on all matters submitted to a vote of the stockholders. If at any time the ratio at which LLC Units are redeemable or exchangeable for shares of Class A common stock changes from one-for-one, the number of votes to which Class B common stockholders are entitled will be adjusted accordingly. The holders of Class B common stock do not have cumulative voting rights in the election of directors. Except for transfers to Signify Health pursuant to the Cure TopCo Amended LLC Agreement or to certain permitted transferees, the LLC Units and corresponding shares of Class B common stock may not be sold, transferred or otherwise disposed of. Holders of shares of Class B common stock will vote together with holders of Class A common stock as a single class on all matters on which stockholders are entitled to vote, except as otherwise required by law. The Class B common stock is not entitled to economic interests in Signify Health. Holders of Class B common stock do not have any right to receive dividends or to receive a distribution upon a liquidation or winding up of Signify Health. However, if Cure TopCo makes distributions to Signify Health, the other holders of LLC Units, including the Continuing Pre-IPO LLC Members, will be entitled to receive distributions pro rata in accordance with the percentages of their respective LLC Units. The Class B common stock is not subject to further calls or assessment. Cure TopCo, LLC Recapitalization As noted above, in connection with our IPO, the limited liability company agreement of Cure TopCo was amended and restated (the “Cure TopCo LLCA”) to, among other things, convert all outstanding equity interests into LLC Units and appoint us as the sole managing member of Cure TopCo. Under the Cure TopCo LLCA, holders of LLC Units have the right to require Cure TopCo to redeem all or a portion of their LLC Units for newly issued shares of our Class A common stock on a one-for-one basis or a cash payment equal to the volume-weighted average market price of one share of our Class A common stock for each LLC Unit redeemed. This will result in the recognition of a contingently redeemable noncontrolling interest in Cure TopCo held by the Continuing Pre-IPO LLC Members, which will be redeemable, at the election of Signify Health, for shares of Class A common stock on a one-for-one basis or a cash payment in accordance with the terms of the Cure TopCo LLCA and which, if the redeeming member is an affiliate, the decision to redeem in cash or shares will be approved by the disinterested members of the Audit Committee. Cure TopCo Membership Units

Noncontrolling Interest

Noncontrolling Interest	9 Months Ended
	Sep. 30, 2021
Noncontrolling Interest [Abstract]
Noncontrolling Interest	Noncontrolling InterestIn connection with the Reorganization Transactions, we became the sole manager of Cure TopCo and, as a result of this control, and because we have a substantial financial interest in Cure TopCo, we consolidate the financial results of Cure TopCo into our Condensed Consolidated Financial Statements. The contingently redeemable noncontrolling interest represents the economic interests of Cure TopCo held by the holders of LLC Units other than the membership units held by us. Income or loss is attributed to the noncontrolling interests based on the relative percentages of LLC Units held by us and the other holders of LLC Units during the period. As such, future redemptions or direct exchanges of LLC Units will result in a change in ownership and reduce or increase the amount recorded as noncontrolling interests and increase or decrease additional paid-in capital in the Condensed Consolidated Balance Sheets. The following table summarizes the ownership interests in Cure TopCo as of September 30, 2021: LLC Units Ownership Percentage Number of LLC Units held by Signify Health, Inc. 170,355,960 75.1% Number of LLC Units held by noncontrolling interests 56,482,324 24.9% Total LLC Units outstanding 226,838,284 100.0% LLC Units held by the Continuing Pre-IPO LLC Members are redeemable or exchangeable for, at our election and with appropriate approvals, newly issued shares of Class A common stock on a one-for-one basis or a cash payment in accordance with the terms of the Cure TopCo LLCA. During the three and nine months ended September 30, 2021, 1,748,451 LLC units were exchanged by Continuing Pre-IPO LLC Members, and shares of Class A common stock were issued on a one-for-one basis.

Equity-Based Compensation

Equity-Based Compensation	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Equity-Based Compensation	Equity-Based Compensation 2021 Long-Term Incentive Plan In January 2021, our Board of Directors adopted the 2021 Long-Term Incentive Plan (the “2021 LTIP”) which became effective in connection with the IPO and provides for the grant of equity-based awards to employees, consultants, service providers and non-employee directors. At inception, there were 16,556,298 shares of Class A common stock available for issuance under the 2021 LTIP. The share pool will be increased on the first day of each year by the least of (i) 14,191,113 shares of Class A common stock, (ii) 3% of the aggregate number of shares of Class A common stock and shares of Class B common stock outstanding (on a fully diluted basis) on the last day of the immediately preceding fiscal year and (iii) an amount determined by the Board of Directors. Any shares underlying substitute awards, shares remaining available for grant under a plan of an acquired company and awards (including pre-IPO awards (as defined in the 2021 LTIP)) that are forfeited, cancelled, expired, terminated or are otherwise lapsed, in whole or in part, or are settled in cash or withheld in respect of taxes, will become available for future grants under the 2021 LTIP. During the three and nine months ended September 30, 2021, we issued under the 2021 LTIP, 335,355 and 1,368,805 stock options, respectively, at a weighted average exercise price of $27.21 and $25.04, respectively, to certain members of management of Cure TopCo that are subject to time-based vesting and vest ratably over either three In addition, during the three and nine months ended September 30, 2021, we issued under the 2021 LTIP, 155,039 and 306,919 restricted stock units (“RSUs”), respectively, to members of our Board of Directors that vest on the one-year anniversary of the grant date and to certain members of management of Cure TopCo that vest ratably over four years. The grant date fair value of these RSUs was $8.0 million and will be recognized as stock-based compensation expense over the vesting period. During the three and nine months ended September 30, 2021, we recognized $0.8 million and $1.5 million, respectively, of equity-based compensation expense included in SG&A expense on the Condensed Consolidated Statements of Operations related to RSUs issued under the 2021 LTIP. As of September 30, 2021, there were 290,419 RSUs outstanding and 1,294,305 stock options at a weighted average exercise price of $25.01 under the 2021 LTIP. As of September 30, 2021, there was $19.6 million of total unrecognized compensation expense related to unvested time-based awards issued under the 2021 LTIP expected to be recognized over a weighted average period of 1.5 years. Employee Stock Purchase Plan In January 2021, our Board of Directors also approved the 2021 Employee Stock Purchase Plan (“ESPP”), which became effective on July 1, 2021. The ESPP provides employees and employees of participating subsidiaries with an opportunity to acquire a proprietary interest in the Company through the purchase of shares of Class A common stock. Initially, the ESPP will not qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code of 1986, as amended (the “Code”). From and after such date as the Compensation Committee, in its discretion, determines that the ESPP is able to satisfy the requirements under Section 423 of the Code and that it will operate the ESPP in accordance with such requirements, the ESPP will qualify as an “employee stock purchase plan” under Section 423 of the Code and the ESPP will be interpreted in a manner that is consistent with that intent. There are 4,730,371 shares of Class A common stock available for issuance under the ESPP. The share pool will be increased on the first day of each fiscal year in an amount equal to the lesser of (i) 4,730,371 shares of Class A common stock and (ii) 1% of the aggregate number of shares of Class A common stock and Class B common stock outstanding (on a fully diluted basis) on the last day of the immediately preceding fiscal year. The first purchase under the ESPP will be made on December 31, 2021. During the three and nine months ended September 30, 2021, we recognized $0.2 million of equity-based compensation expense included in SG&A expense on the Condensed Consolidated Statements of Operations related to the ESPP. Incentive Units In connection with the Reorganization Transactions and pursuant to the Cure TopCo LLCA and the Fourth Amended and Restated Limited Liability Company Agreement of Cure Aggregator, LLC (the “Aggregator LLCA”) adopted in connection with the IPO, all units of membership interests in Cure TopCo existing immediately prior to the Reorganization Transactions were reclassified and converted into LLC units of Cure TopCo and all outstanding Class B units and Class C units in Cure Aggregator, which correspond to Class B units and Class C units issued by Cure TopCo to Cure Aggregator and were intended to be treated as profits interests for U.S. federal income tax purposes, were reclassified and converted into common units of Cure Aggregator (the “Incentive Units”) based on the value and terms of the underlying Cure TopCo LLCA and Aggregator LLCA. The incentive units will remain outstanding and subject to their original vesting schedules. No further Incentive Units will be granted. As of September 30, 2021, there were 13,555,806 Incentive Units outstanding, of which 8,208,887 are unvested. This includes 5,977,283 subject to performance-based vesting criteria which were not probable of occurring as of September 30, 2021. The conversion of the outstanding profits interests as a result of the Reorganization Transactions did not result in any incremental expense as the fair value at the time of modification did not exceed the fair value of the previous award immediately prior to the modification. Accordingly, we continue to recognize the original grant date fair value of the Incentive Units. During the three months ended September 30, 2021 and 2020, we recognized $1.5 million and $1.7 million, respectively, of equity-based compensation expense related to Incentive Units. Of this total expense, $1.4 million and $1.6 million were included in SG&A expense and $0.1 million and $0.1 million were included in service expense on the Condensed Consolidated Statements of Operations for the three months ended September 30, 2021 and 2020, respectively. During the nine months ended September 30, 2021 and 2020, we recognized $4.4 million and $8.7 million, respectively, of equity-based compensation expense related to Incentive Units. Of this total expense, $4.3 million and $8.6 million were included in SG&A expense and $0.1 million and $0.1 million were included in service expense on the Condensed Consolidated Statements of Operations for the nine months ended September 30, 2021 and 2020, respectively. As of September 30, 2021, there was $6.9 million of total unrecognized compensation expense related to unvested time-based Incentive Units expected to be recognized over a weighted average period of 0.8 years. Additionally, there was approximately $13.2 million of unrecognized compensation expense related to Incentive Units with performance-based vesting, in which the vesting conditions were not probable of occurring as of September 30, 2021. Amended and Restated 2012 and 2019 Equity Incentive Plans In connection with the Reorganization Transactions, all New Remedy Corp. stock options outstanding were converted into stock options to purchase shares of our Class A common stock. The conversion was based on the values and terms of the Signify Health, Inc. Amended and Restated 2012 and 2019 Equity Incentive Plans and agreements entered into in connection with the Reorganization Transactions. The conversion of the outstanding stock options did not result in any incremental expense as the number of stock options outstanding and the exercise price were both adjusted on a proportionate basis, and therefore, the fair value of the new award did not exceed the fair value of the previous award immediately prior to the modification. The outstanding stock options remain subject to their original vesting schedules. Accordingly, we continue to recognize the original grant date fair value of these converted stock options now outstanding under the Signify Health, Inc. Amended and Restated 2012 and 2019 Equity Incentive Plans. No future grants of equity will be made under these plans. As of September 30, 2021, there were 4,985,782 stock options outstanding at a weighted average exercise price of $6.07. This includes 977,248 subject to performance-based vesting criteria which were not probable of occurring as of September 30, 2021. During the three months ended September 30, 2021 and 2020, we recognized $0.3 million and $0.4 million, respectively, of equity-based compensation expense related to outstanding stock options included in SG&A expense on the Condensed Consolidated Statements of Operations. During the nine months ended September 30, 2021 and 2020, we recognized $1.0 million and $1.3 million, respectively, of equity-based compensation expense related to outstanding stock options under the Amended and Restated 2012 and 2019 Equity Incentive Plans included in SG&A expense on the Condensed Consolidated Statements of Operations. As of September 30, 2021, there was $2.2 million of total unrecognized compensation expense related to unvested time-based stock options under the Amended and Restated 2012 and 2019 Equity Incentive Plans expected to be recognized over a weighted average period of 0.9 years. Additionally, there was approximately $2.1 million of unrecognized compensation expense related to stock options with performance-based vesting, in which the vesting conditions are not probable of occurring as of September 30, 2021.

Earnings (Loss) Per Share

Earnings (Loss) Per Share	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	Earnings (Loss) Per Share Basic earnings (loss) per share of Class A common stock is computed by dividing net income (loss) attributable to Signify Health by the weighted-average number of shares of Class A common stock outstanding during the period. Diluted earnings (loss) per share of Class A common stock is computed by dividing net income (loss) available to Signify Health by the weighted-average number of shares of Class A common stock outstanding adjusted to give effect to potentially dilutive securities. We analyzed the calculation of earnings (loss) per unit for the period prior to the IPO and determined that it resulted in values that would not be meaningful to the users of these unaudited Condensed Consolidated Financial Statements due to the significant nature of the Reorganization Transactions on the capital structure. Therefore, earnings (loss) per unit information has not been presented for the three and nine months ended September 30, 2020. The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted earnings (loss) per share of Class A common stock for the three and nine months ended September 30, 2021. The basic and diluted earnings (loss) per share for the nine months ended September 30, 2021 represents only the period from February 12, 2021 to September 30, 2021, which represents the period wherein we had outstanding Class A common stock. Three months ended September 30, 2021 Nine months ended September 30, 2021 (in millions) Net income (loss) $ 29.3 $ (22.5) Less: Net income (loss) attributable to pre-Reorganization Transactions — (17.2) Less: Net income (loss) attributable to the noncontrolling interest 9.1 (2.3) Net income (loss) attributable to Signify Health, Inc. $ 20.2 $ (3.0) Weighted average shares of Class A common stock outstanding - Basic 169,055,078 167,905,136 Dilutive Shares: Stock Options 3,332,831 — RSUs 46,041 — LLC Units — — Total Dilutive shares 3,378,872 — Weighted average shares of Class A common stock outstanding - Diluted 172,433,950 167,905,136 Earnings (loss) per share of Class A common stock - Basic $ 0.12 $ (0.02) Earnings (loss) per share of Class A common stock - Diluted $ 0.12 $ (0.02) Shares of Class B common stock do not participate in our earnings or losses and are therefore not participating securities. As such, separate presentation of basic and diluted loss per share of Class B common stock under the two-class method has not been presented. Shares of our Class B common stock and the corresponding LLC Units are, however, considered potentially dilutive shares of Class A common stock. LLC Units of Cure TopCo participate in the earnings of Cure TopCo and therefore, our portion of Cure TopCo’s earnings (loss) per share has been included in the net income (loss) attributable to Signify Health in the calculation above. LLC Units held by the Continuing Pre-IPO LLC Members are redeemable in accordance with the Cure TopCo LLCA, at the election of Signify Health, for shares of Class A common stock on a one-for-one basis or a cash payment. The potential dilutive effect of LLC Units are evaluated under the if-converted method. The potential dilutive effect of stock options and RSUs are evaluated under the treasury stock method. The following table summarizes the stock options, RSUs, and weighted-average LLC Units that were anti-dilutive for the periods indicated. As a result, these shares, which were outstanding, were excluded from the computation of diluted earnings per share for the periods indicated: Three months ended September 30, 2021 Nine months ended September 30, 2021 Antidilutive Shares: Stock Options 1,294,305 5,302,839 RSUs 149,539 290,419 LLC Units 58,713,929 58,713,929 Additionally, 977,247 stock options and 5,977,283 LLC units were excluded from the calculation of earnings (loss) per share for the three and nine months ended September 30, 2021 as they are subject to performance vesting conditions, which are not probable of occurring as of September 30, 2021.

Transaction-related Expenses

Transaction-related Expenses	9 Months Ended
	Sep. 30, 2021
Other Income and Expenses [Abstract]
Transaction-related Expenses	Transaction-related ExpensesDuring the three and nine months ended September 30, 2021, we incurred $2.9 million and $4.8 million, respectively, of transaction-related expenses in connection with corporate development activities, such as potential mergers and acquisitions, strategic investments and other similar activities. These transaction-related expenses primarily related to consulting and other professional services expenses. Additionally, during the nine months ended September 30, 2021, we incurred $4.7 million of costs in connection with our IPO. For the three and nine months ended September 30, 2020, we incurred $5.9 million and $9.9 million, respectively, of transaction-related expenses related to the integration of Remedy Partners as well as expenses incurred in connection with corporate development activities, such as potential mergers and acquisitions, strategic investments and other similar activities. These transaction-related expenses related to consulting, compensation, and integration-type expenses. Additionally, for the three and nine months ended September 30, 2020 we incurred $0.9 million of costs in connection with our IPO.

Commitment and Contingencies

Commitment and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Lease Commitments Effective October 1, 2021, we entered into a new lease agreement for a facility in Oklahoma City, OK. The lease term is 7.25 years, with two 5-year options to renew, and total lease payments are expected to be approximately $4.2 million. Letters of Credit As of September 30, 2021, we had outstanding letters of credit totaling $9.2 million in favor of CMS, which are required in the event of a negative outcome on certain episodes of care within the BPCI-A program and we do not settle the related amounts owed to CMS. This amount reduces the borrowing amount available to us under our Revolving Credit Facility as of September 30, 2021 . See Note 10 Long-Term Debt for the total value of letters of credit under this facility. However, the terms of BPCI-A also require that certain partners provide a related reciprocal letter of credit for the majority of this amount. As of September 30, 2021, there are three related letters of credit totaling $8.8 million. Contingencies Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties and other sources are recorded when it is probable a liability has been incurred and the amount of the liability can be reasonably estimated. We are involved in various lawsuits, claims and administrative proceedings arising in the normal course of business. In management’s opinion, the ultimate resolution of these matters will not materially adversely affect our financial position, results of operations or cash flows. Sales Tax Reserve During the year ended December 31, 2019, it was determined that certain Episodes of Care Services may be subject to sales tax in certain jurisdictions. Historically, we had not collected sales tax from our Episodes of Care Services customers as we believed the services were not taxable. As of September 30, 2021 and December 31, 2020, we had a liability of $3.8 million and $8.0 million, respectively, for potential sales tax exposure related to services performed in 2016 through the second quarter of 2020, included in other current liabilities on the Condensed Consolidated Balance Sheets. We are in the process of settling this potential exposure with the various states and we began collecting sales tax from customers in the second quarter of 2021 for 2020 services. Equity Appreciation Rights In December 2019, we entered into an EAR agreement with a customer, which contains the following provisions: (i) established certain revenue targets for the customer to meet with one of our wholly-owned indirect operating subsidiaries for the subsequent three years in accordance with specific terms and conditions and (ii) granted the customer a contingent EAR. The EAR agreement allows for the customer to participate in the future growth in the fair market value of our equity and can only be settled in cash (or, under certain circumstances, in whole or in part with a replacement agreement that mimics the economics of the original EAR agreement) upon a change in control, other liquidity event, or upon approval of our Board of Directors with consent by New Mountain Capital with certain terms and conditions. The EAR will expire in 20 years from the date of grant, if not previously settled. The initial fair value of the EAR is being recorded as a reduction of revenue as this represents consideration payable to a customer, and subsequent changes in fair value are being recorded as other income (expense), net. Although the initial EAR agreement was executed in December 2019, the service period did not begin until 2020 and, therefore, there was no impact on our results of operations until 2020. The grant date fair value of this EAR was estimated to be $15.2 million and is being recorded as a reduction of revenue through December 31, 2022, coinciding with the three year performance period. Effective September 2020, we entered into a second EAR agreement with the same customer, containing similar provisions to the EAR agreement entered into in December 2019. We concurrently entered into an amended customer contract which included incremental IHE volume from the customer beginning in 2020. The grant date fair value of this EAR was estimated to be $36.6 million and is being recorded as a reduction of revenue through December 31, 2022, coinciding with the 2.5 year performance period. As of September 30, 2021, there was approximately $24.6 million of original grant date fair value unrecognized, which we expect to record as a reduction of revenue over the next 1.25 years. We remeasure the fair value of the outstanding EAR agreements at the end of each reporting period and record any changes in fair value to other expense (income), net in our Condensed Consolidated Statement of Operations. See Note 11 Fair Value Measurements for changes in estimated fair value and valuation techniques used to estimate the EAR. Synthetic Equity Plan On February 14, 2020, our Board of Directors adopted a Synthetic Equity Plan (“SEP”) that provides for cash payments upon the satisfaction of certain criteria. The synthetic equity units granted under the SEP were subject to time and performance vesting and were to be paid upon a change in control (as defined in the SEP) based upon the difference in the value of the Company at the time of the change in control event and a "floor amount". Since the vesting criteria were not probable of occurring as of September 30, 2020, we had not recognized any compensation expense related to these awards for the three or nine months ended September 30, 2020. In February 2021, the SEP was amended to, among other things, remove the change in control payment condition and provide for cash settlement upon each vesting event based on a 30 day volume weighted average price of our Class A common shares. As a result of this amendment, we began to record compensation expense and a current liability beginning in the first quarter of 2021 related to outstanding synthetic equity awards subject to time-based vesting. The liability and expense are adjusted each reporting period based upon actual cash settlements and the underlying value of our Class A common stock. The SEU liability is included in accounts payable and accrued expenses on our Condensed Consolidated Balance Sheet. We have not recorded any expense related to the outstanding synthetic equity awards subject to performance-based vesting as the vesting criteria were not probable of occurring as of September 30, 2021. As of September 30, 2021, 446,880 synthetic equity units outstanding are subject to time-based vesting and 119,623 synthetic equity units outstanding are subject to performance-based vesting. The following table summarizes the change in the SEU liability: Three months ended September 30, 2021 Nine months ended September 30, 2021 (in millions) Balance at beginning of period $ 0.7 $ — SEU expense included in service expense — 0.6 SEU expense included in SG&A expense 0.2 1.4 Cash payments (0.2) (1.3) Balance at end of period $ 0.7 $ 0.7 Contingent Consideration

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income tax (benefit) expense for the three months ended September 30, 2021 and 2020, was $6.4 million and $0.2 million, respectively, and for the nine months ended September 30, 2021 and 2020, was $(3.7) million and $0.5 million, respectively. Our estimated effective tax rate for the three and nine months ended September 30, 2021 was 18.0% and 13.9%, respectively. Our estimated annual effective tax rate is less than the statutory rate of 21% primarily because we are not liable for income taxes on the portion of earnings that are attributable to the non-controlling interest. As a result of the IPO, we recorded a change in the net deferred tax asset position, net of valuation allowance, of $29.0 million, which primarily consisted of the outside basis differences in our partnership subsidiaries. In assessing the realizability of deferred tax assets, including the deferred tax assets recorded as a result of the IPO and current year operations, management determined that it was more likely than not that the deferred tax assets will be realized. As of December 31, 2020, PatientBlox had U.S. federal net operating loss carryforwards for tax purposes aggregating approximately $6.2 million which have an indefinite carryforward period; however, these can only reduce taxable income in a future period by a maximum of 80%. All of these net operating loss carryforwards are subject to certain rules under Internal Revenue Code (“IRC”) Section 382. We believe these IRC Section 382 limitations will not ultimately affect our ability to use substantially all of the net operating loss carryforwards for income tax purposes. We have not offset any of the net deferred tax assets, including net operating loss carryforwards, with a valuation allowance for the tax periods ended December 31, 2020 due to existing taxable temporary differences that are a source of income supporting realization of the deferred tax assets. Uncertain Tax Provisions We evaluate and account for uncertain tax positions taken or expected to be taken on an income tax return using a two-step approach. Step one, recognition, occurs when we conclude that a tax position, based solely on its technical merits, is more-likely-than-not to be sustainable upon examination. Step two, measurement, determines the amount of benefit that is greater than 50% likely to be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. Derecognition of a tax position that was previously recognized would occur when we subsequently determine that a tax position no longer meets the more likely-than-not threshold of being sustained. We record interest (and penalties where applicable), net of any applicable related income tax benefit, on potential income tax contingencies as a component of income tax provision. We have evaluated our tax positions and have not identified any material uncertain tax positions for which a reserve should be recorded. Accordingly, no provision for uncertainties in income taxes has been made in the accompanying Condensed Consolidated Financial Statements as of September 30, 2021. Tax Receivable Agreement In February 2021, in connection with the Reorganization Transactions and IPO, we entered into the Tax Receivable Agreement (the “TRA”), which obligates us to make payments to the Continuing Pre-IPO LLC Members, the Reorganization Parties, Optionholders (as defined in the TRA) of the Blocker Companies at the time of the Mergers, holders of synthetic equity units and any future party to the TRA (collectively, the “TRA Parties”) in the aggregate generally equal to 85% of the applicable cash savings that we actually realize as a result of (i) certain favorable tax attributes acquired from the Blocker Companies in the Mergers (including net operating losses, the Blocker Companies’ allocable share of existing tax basis and refunds of Blocker Company taxes attributable to pre-Merger tax periods), (ii) increases in our allocable share of existing tax basis and tax basis adjustments that may result from (x) future redemptions or exchanges of LLC Units by Continuing Pre-IPO LLC Members for cash or Class A common stock, (y) the IPO Contribution and (z) certain payments made under the TRA and (iii) deductions in respect of interest and certain compensatory payments made under the TRA. We will retain the benefit of the remaining 15% of these tax savings. As of September 30, 2021, we had a liability of $59.6 million related to the projected obligations under the TRA. TRA related liabilities are classified as current or noncurrent based on the expected date of payment. During the three months ended September 30, 2021, we recorded an increase in the TRA liability of $8.3 million due to exchanges of LLC units, which created an increase in deferred tax assets. As of September 30, 2021, there are no amounts due within 12 months and therefore the entire liability is included in Tax receivable agreement liability within noncurrent liabilities on our Condensed Consolidated Balance Sheet.

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Segment Reporting	Segment Reporting Operating segments are components of an enterprise for which separate financial information is available and evaluated regularly by our Chief Operating Decision Maker in deciding how to allocate resources and in assessing financial performance. Management views our operating performance in two reportable segments: Home & Community Services and Episodes of Care Services. We evaluate the performance of each segment based on segment revenue and adjusted EBITDA. The operating results of the reportable segment are based on segment adjusted EBITDA, which includes revenue and expenses incurred by the segment, as well as an allocation of shared expenses. Shared expenses are generally allocated to each segment based on the segments’ proportionate employee headcount. Certain costs are not allocated to the segments, as described below, as these items are not considered in evaluating the segment’s overall performance. See Note 5 Revenue Recognition for a summary of segment revenue by product type for the three and nine months ended September 30, 2021 and 2020. Our operating segment results for the periods presented were as follows: Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 (in millions) (in millions) Revenue Home & Community Services $ 169.1 $ 114.7 $ 496.9 $ 301.8 Episodes of Care Services 30.1 40.0 95.1 115.3 Segment Adjusted EBITDA Home & Community Services 49.9 20.8 146.8 65.8 Episodes of Care Services (7.9) 7.9 (15.8) 20.2 Less: reconciling items to net loss: Unallocated costs (1) (15.5) 20.9 88.1 38.5 Depreciation and amortization 17.6 15.8 51.6 46.0 Interest expense 4.2 5.1 17.5 16.2 Loss before income taxes $ 35.7 $ (13.1) $ (26.2) $ (14.7) (1) Unallocated costs as follows: Other (income) expense, net (2) (27.4) 6.3 43.6 6.9 Loss on Debt Extinguishment — — 5.0 — Equity-based compensation 3.7 2.1 9.5 10.0 SEU Expense 0.2 — 2.0 — Customer equity appreciation rights 5.0 4.9 14.8 7.5 Transaction-related expenses 2.9 6.8 9.5 10.8 Non-allocated costs (3) 0.1 0.8 3.7 3.3 Total unallocated costs $ (15.5) $ 20.9 $ 88.1 $ 38.5 (2) Other (income) expense, net includes the remeasurement of the fair value of the outstanding customer EAR. (3) Non-allocated costs included remeasurement of contingent consideration, management fees paid to our capital partner and certain non-recurring expenses, including those associated with the closure of certain facilities, the sale of certain assets, one-time expenses related to the COVID-19 pandemic and the early termination of certain contracts. These costs are not considered by our Chief Operating Decision Maker in making resource allocation decisions. Our Chief Operating Decision Maker does not receive or utilize asset information to evaluate performance of operating segments. Accordingly, asset-related information has not been presented.

Concentrations

Concentrations	9 Months Ended
	Sep. 30, 2021
Risks and Uncertainties [Abstract]
Concentrations	Concentrations During the normal course of operations, we maintain cash in bank accounts which exceed federally insured amounts. We have not experienced any losses in such accounts and do not believe we are exposed to any significant credit risk related to cash. Accounts receivable potentially subject us to concentrations of credit risk. Management believes that its contract acceptance, billing and collection policies are adequate to minimize potential credit risk. We continuously evaluate the credit worthiness of our customers’ financial condition and generally do not require collateral. We are dependent on a concentrated number of payors and provider partners with whom we contract to provide IHEs and other services. A significant portion of our revenues are generated from a small number of customers. For the three months ended September 30, 2021, we had four customers which accounted for approximately 21%, 24%, 12%, and 12%, respectively, of total revenues, and for the nine months ended September 30, 2021, we had three customers which accounted for approximately 25%, 24%, and 12%, respectively, of total revenues. In addition, the revenue from our top ten customers accounted for approximately 77% and 78% of our total revenue for the three and nine months ended September 30, 2021, respectively. As of September 30, 2021, we had four customers which accounted for approximately 18%, 15%, 13%, and 10%, respectively, of accounts receivable.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions In connection with the Reorganization Transactions, we entered into several agreements with various parties including CureTopCo, New Mountain Capital and its affiliates, certain members of management and other shareholders. These include the Reorganization Agreement, the Cure TopCo, LLC Agreement, the TRA, the Registration Rights Agreement and the Stockholders' Agreement, all of which are fully described in our 2020 Annual Report on Form 10-K. See Note 1 Nature of Operations for further details on the Reorganization Transactions. See Note 12 Shareholders' Equity for additional information on the Cure TopCo, LLC Recapitalization. See Note 18 Income Taxes for additional information on the TRA. On March 7, 2019, we entered into a consulting agreement with Bret Carlson, a former director, which provided for $0.3 million annually (payable monthly) in compensation for consulting services provided to us. In the event that we complete a corporate transaction in which we acquire all of the equity interests or all, or substantially all, of the assets of a company in our industry referred to and introduced to us by Mr. Carlson, Mr. Carlson will be eligible to receive a cash transaction fee of 3% of any deal consideration up to $10 million, plus an additional 1.5% on any incremental deal consideration above $10 million. On November 23, 2020, we entered into a letter agreement with Kevin McNamara, a director, which provided for payment of $0.1 million and $0.2 million for the three and nine months ended September 30, 2020, respectively, (payable in accordance with the Company’s payroll practices) in compensation for non-director related services provided to us. In addition, Mr. McNamara was entitled to reimbursement for annual premiums on life, accidental death and dismemberment, short-term disability and medical insurance. This agreement terminated effective March 1, 2021, as Mr. McNamara is now paid in accordance with our Director compensation policy.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation These Condensed Consolidated Financial Statements are unaudited and have been prepared by us in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and following the rules and regulations of the Securities and Exchange Commission (the “SEC”). The financial statements included in this report should be read in conjunction with the Company’s audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020. In our opinion, they reflect all adjustments, including normal recurring items, that are necessary to present fairly the results of interim periods. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted as permitted by such rules and regulations; however, we believe that the disclosures are adequate to make the information presented not misleading. Operating results for the periods presented herein are not necessarily indicative of the results that may be expected for future interim periods or the entire fiscal year. Our quarterly results of operations, including our revenue, income (loss) from operations, net income (loss) and cash flows, have varied and may vary significantly in the future; therefore, period-to-period comparisons of our results of operations may not be meaningful. Accordingly, our interim results should not be relied upon as an indication of future performance.
Consolidation	For the periods subsequent to the Reorganization Transactions effective February 12, 2021, the Condensed Consolidated Financial Statements represent Signify Health and our consolidated subsidiaries, including Cure TopCo. For the periods prior to the Reorganization Transactions, the condensed consolidated financial statements represent Cure TopCo and its consolidated subsidiaries, see Note 1 Nature of Operations . Signify Health was formed for the purpose of the IPO, which was effective in February 2021 and had no activities of its own prior to such date. We are a holding company and our sole material asset is a controlling ownership interest in Cure TopCo. The Condensed Consolidated Financial Statements include the accounts and financial statements of our wholly-owned subsidiaries and variable interest entities (“VIE”s) where we are the primary beneficiary. Results of operations of VIEs are included from the dates we became the primary beneficiary. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The accompanying Condensed Consolidated Financial Statements have been prepared in conformity with GAAP, which requires management to make estimates and assumptions affecting the reported amounts in our Condensed Consolidated Financial Statements and accompanying notes. These estimates are based on information available as of the date of the Condensed Consolidated Financial Statements; therefore, actual results could differ from those estimates. The significant estimates underlying our Condensed Consolidated Financial Statements include revenue recognition; allowance for doubtful accounts; recoverability of long-lived assets, intangible assets and goodwill; loss contingencies; accounting for business combinations, including amounts assigned to definite and indefinite lived intangible assets and contingent consideration; and equity-based compensation. As of September 30, 2021, the impact of the COVID-19 pandemic continues to unfold particularly on our Episodes of Care Services segment due to the passage of time between episode initiation and the performance and subsequent recognition of revenue for our services; See Note 3 The COVID-19 Pandemic . As a result, many of our estimates and assumptions have required increased judgment and carry a higher degree of variability and volatility. As events continue to evolve and additional information becomes available, our estimates may change materially in the future.
Comprehensive Income (Loss)	Comprehensive Income (Loss) We have not identified any incremental items that would be considered a component of comprehensive income (loss) and accordingly a statement of comprehensive income (loss) is not reflected in the Condensed Consolidated Financial Statements because net income (loss) and comprehensive income (loss) are the same.
Restricted Cash	Restricted Cash Under our Master Agreement with the Centers for Medicare and Medicaid Services (“CMS”), we were required to place certain funds in escrow for the benefit of CMS. These amounts, known as a Secondary Repayment Source (“SRS”), were primarily based on the size of our participation in the legacy CMS Bundled Payments for Care Improvement (“BPCI”) program, the predecessor program of the Bundled Payments for Care Improvement - Advanced initiative (“BPCI-A”). These funds were available to CMS as a supplemental payment source if we failed to pay amounts owed to CMS. Under the agreement, the funds are returned to us 18 months after the conclusion of the effective period of the CMS Master Agreement, or when all financial obligations to CMS are fulfilled. As of September 30, 2021 and December 31, 2020, there were $0.5 million in the SRS account included in restricted cash on the Condensed Consolidated Balance Sheets related to BPCI-A. We also withhold a portion of shared savings to customers in a “holding pool” to cover any potential subsequent negative adjustments through CMS’s subsequent reconciliation true-up process. These funds are distributed to customers following the final true-up if there is no negative adjustment. These amounts represent consideration payable to the customer and therefore have reduced revenue in the period earned. The funds have been received by us from CMS and are held in a separate cash account, included as restricted cash on the Condensed Consolidated Balance Sheets. Since the funds are payable to the customer at the point the final CMS true-up is made or a negative adjustment is due to us, the amounts are also included in accounts payable and accrued expenses on the Condensed Consolidated Balance Sheets. As of September 30, 2021 and December 31, 2020, there was $6.6 million and $3.5 million of restricted cash in the holding pool, respectively. As of December 31, 2020, we held $0.4 million of restricted cash, acquired as part of the PatientBlox acquisition. During the second quarter of 2021, in connection with the successful completion of the first earn out milestone outlined in the acquisition agreement, the balance of the restricted cash was released and paid to the sellers. As a result, there is no remaining balance of restricted cash related to the PatientBlox acquisition as of September 30, 2021.
Accounts Receivable	Accounts ReceivableAccounts receivable primarily consist of amounts due from customers and CMS and are stated at their net realizable value. Management evaluates all accounts periodically and an allowance is established based on the latest information available to management. Management considers historical realization data, accounts receivable aging trends and other operational trends to estimate the collectability of receivables. After all reasonable attempts to collect a receivable have been exhausted, the receivable is written off against the allowance for doubtful accounts.
Advertising and Marketing Cost	Advertising and Marketing CostsAdvertising and marketing costs are included in SG&A expenses and are expensed as incurred.
Income Taxes	Income Taxes We are organized as a C Corporation and own a controlling interest in Cure TopCo which is organized as a partnership for tax purposes. For partnership and disregarded entities, taxable income and the resulting liabilities are allocated among the owners of the entities and reported on the tax filings for those owners. We record income tax (benefit) expense, deferred tax assets, and deferred tax liabilities only for the items for which we are responsible for making payments directly to the relevant tax authority. Deferred income taxes reflect the net tax effects of temporary differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws expected to be in effect when such differences are expected to reverse. Such temporary differences are reflected as deferred tax assets and deferred tax liabilities on the Condensed Consolidated Balance Sheets. A deferred tax asset is recognized if it is more likely than not that a tax benefit will be realized. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some or all of the deferred tax assets will be realized and, when necessary, a valuation allowance is established. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences become deductible. We may recognize tax liabilities when, despite our belief that our tax return positions are supportable, we believe that certain positions may not be fully sustained upon review by the tax authorities. Benefits from tax positions are measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon settlement. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences impact income tax expense in the period such determination is made. We recognize interest and penalties related to income taxes as a component of income tax expense.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recently Adopted In June 2018, the FASB issued Accounting Standards Update No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”) . The amendments in ASU 2018-07 expanded the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 is effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. We elected to early adopt this new guidance for interim periods in 2020 with no significant impact to our financial statements. In November 2019, the FASB issued ASU 2019-08, Compensation – Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Codification Improvements – Share-Based Consideration Payable to a Customer (“ASU 2019-08”). ASU 2019-08 requires that an entity measure and classify share-based payment awards granted to a customer by applying the guidance in Topic 718. The amount recorded as a reduction of the transaction price is required to be measured on the basis of the grant-date fair value of the share-based payment award in accordance with Topic 718. The grant date is the date at which a grantor (supplier) and a grantee (customer) reach a mutual understanding of the key terms and conditions of a share-based payment award. ASU 2019-08 is effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. We elected to early adopt this new guidance for interim periods in 2020, which had an impact on the customer Equity Appreciation Rights (“EAR”) agreements. The initial grant date fair value of the EAR agreements is being recorded as a reduction of the transaction price beginning in 2020. See Note 17 Commitments and Contingencies . Pending Adoption We are an “emerging growth company” under the Jumpstart Our Business Startups Act (“JOBS Act”). Pursuant to the JOBS Act, an emerging growth company is provided the option to adopt new or revised accounting standards that may be issued by FASB or the SEC either (i) within the same periods as those otherwise applicable to non-emerging growth companies or (ii) within the same time periods as private companies. We intend to take advantage of the exemption for complying with new or revised accounting standards within the same time periods as private companies. The effective dates below are the effective dates we expect to adopt the new accounting pronouncements, which are those permitted for a company that is not an issuer. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) which requires lessees to recognize leases on the balance sheet by recording a right-of-use asset and lease liability. This guidance is effective for non-public entities for annual reporting period s beginning after December 15, 2021. Early adoption is permitted. During 2021, we have formed a cross-functional adoption project team and continue to make progress as we plan to adopt this new guidance as of January 1, 2022 and will apply the transition option, whereby prior comparative periods will not be retrospectively presented in the consolidated financial statements. We expect to elect the package of practical expedients not to reassess prior conclusions related to contracts containing leases, lease classification and initial direct costs and the lessee practical expedient to combine lease and non-lease components for all asset classes. We expect to make a policy election to not recognize right-of-use assets and lease liabilities for short-term leases for all asset classes. We continue to evaluate other practical expedients available under the guidance. We are also assessing the impact to our accounting policies, processes, disclosures, and internal control over financial reporting. The cross-functional project team is evaluating our portfolio of leases, which primarily consist of real estate leases, as well as the system, process and policy change requirements needed to implement. We have made progress in gathering the necessary data elements for the complete lease population and a lease accounting system has been selected, with system configuration and implementation underway. We expect to record a right of use asset and corresponding lease liability for all outstanding leases and it is likely that the adoption and recognition of these assets and liabilities will have a material impact to our Condensed Consolidated Balance Sheet given the number of facility leases we currently have. We continue to evaluate the expected impact to our Condensed Consolidated Statements of Operations and Cash Flows. In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326) (“ASU 2016-13”) which introduced the current expected credit losses methodology for estimating allowances for credit losses. ASU 2016-13 applies to all financial instruments carried at amortized cost and off-balance-sheet credit exposures not accounted for as insurance, including loan commitments, standby letters of credit, and financial guarantees. The new accounting standard does not apply to trading assets, loans held for sale, financial assets for which the fair value option has been elected, or loans and receivables between entities under common control. ASU 2016-13 is effective for non-public entities for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. We are evaluating the impact of this new guidance on our financial statements.
Revenue from Contract with Customer	Disaggregation of RevenueWe earn revenue from our two operating segments, Home & Community Services and Episodes of Care Services, under contracts that contain various fee structures. Through our Home & Community Services segment, we offer health evaluations performed either within the patient’s home, virtually or at a healthcare provider facility, primarily to Medicare Advantage health plans (and to some extent, Medicaid). Additionally, we offer certain diagnostic screening and other ancillary services, and through our Signify Community solution, we offer services to address healthcare concerns related to social determinants of health. Through our Episodes of Care Services segment, we primarily provide services designed to improve the quality and efficiency of healthcare delivery by developing and managing episodic payment programs in partnership with healthcare providers, primarily under the BPCI-A program with CMS. Additionally, we provide certain complex care management services. All of our revenue is generated in the United States.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Schedule of Cash and Cash Equivalents	The following table reconciles cash, cash equivalents, and restricted cash per the Condensed Consolidated Statements of Cash Flows to the Condensed Consolidated Balance Sheets: September 30, December 31, 2021 2020 (in millions) Cash and cash equivalents $ 678.8 $ 72.6 Restricted cash 7.1 4.4 Total cash, cash equivalents, and restricted cash $ 685.9 $ 77.0
Schedule of Restricted Cash	The following table reconciles cash, cash equivalents, and restricted cash per the Condensed Consolidated Statements of Cash Flows to the Condensed Consolidated Balance Sheets: September 30, December 31, 2021 2020 (in millions) Cash and cash equivalents $ 678.8 $ 72.6 Restricted cash 7.1 4.4 Total cash, cash equivalents, and restricted cash $ 685.9 $ 77.0

Variable Interest Entities (Tab

Variable Interest Entities (Tables)	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Variable Interest Entities	The carrying amount and classification of the VIEs’ assets and liabilities included in the Condensed Consolidated Balance Sheets, net of intercompany amounts, are as follows: September 30, December 31, 2021 2020 (in millions) ASSETS Current assets Cash and cash equivalents $ 3.7 $ 1.8 Accounts receivable, net 14.3 — Total current assets 18.0 1.8 Total assets $ 18.0 $ 1.8 LIABILITIES AND EQUITY Current liabilities Accounts payable and accrued expenses $ 0.3 $ 0.1 Total current liabilities 0.3 0.1 Total liabilities 0.3 0.1 Company capital 18.8 (0.7) Retained earnings (accumulated deficit) (1.1) 2.4 Total equity 17.7 1.7 Total liabilities and equity $ 18.0 $ 1.8

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following table summarizes disaggregated revenue from contracts with customers by source of revenue, which we believe best presents the nature, amount and timing of revenue. Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 (in millions) (in millions) Evaluations $ 167.1 $ 112.5 $ 490.6 $ 294.9 Other 2.0 2.2 6.3 6.9 Home & Community Services Total Revenue 169.1 114.7 496.9 301.8 Episodes 27.8 37.5 88.5 107.2 Other 2.3 2.5 6.6 8.1 Episodes of Care Services Total Revenue 30.1 40.0 95.1 115.3 Consolidated Revenue Total $ 199.2 $ 154.7 $ 592.0 $ 417.1
Schedule of Contract Assets and Contract Liabilities	The following table provides information about accounts included on the Condensed Consolidated Balance Sheet. September 30, 2021 December 31, 2020 Episodes of Care Services Home & Community Services Total Episodes of Care Services Home & Community Services Total (in millions) Assets Accounts receivable, net (1) $ 33.2 $ 136.0 $ 169.2 $ 183.3 $ 87.3 $ 270.6 Contract assets (2) $ 94.6 $ — $ 94.6 $ 27.8 $ — $ 27.8 Liabilities Shared savings payable (3) $ 43.5 $ — $ 43.5 $ 80.8 $ — $ 80.8 Contract liabilities (4) $ 29.2 $ 4.2 $ 33.4 $ 4.8 $ 1.4 $ 6.2 Deferred revenue (5) $ 0.1 $ 0.9 $ 1.0 $ 2.4 $ 1.4 $ 3.8 (1) Accounts receivable, net for Episodes of Care Services included $4.6 million due from CMS as of September 30, 2021 primarily related to the fourth reconciliation period of the BPCI-A program and reflects a lower program size when compared to December 31, 2020. The remaining amount of accounts receivable for both Episodes of Care Services and Home & Community Services represent amounts to be received from customers. Home & Community Services accounts receivable as of September 30, 2021 reflects strong IHE volume in the third quarter and a return to a higher mix of in-person IHEs compared to vIHEs. (2) Contract assets represent management’s estimate of amounts we expect to receive under the BPCI-A program related to the next two reconciliation periods. As of September 30, 2021, contract assets cover episodes of care commencing in the period October 2020 through September 2021. Estimates for program size and savings rate are based on information available as of the date of the financial statements. We record an estimate of revenue related to these performance obligations over the 13-month period starting in the period the related episodes of care commence and through the estimated receipt of the semi-annual CMS reconciliation file. Any changes to these estimates based on new information will be recorded in the period such information is received. Total savings generated and revenue earned for the episodes of care in which a component of the contract asset recorded as of September 30, 2021 relates to, will be included in the semi-annual reconciliation expected from CMS during the fourth quarter of 2021. (3) Total shared savings payable is included in accounts payable and accrued expenses on the Condensed Consolidated Balance Sheets. Shared savings payable for Episodes of Care Services included $0.3 million due to CMS as of September 30, 2021, which we expect to settle with CMS during the next semi-annual reconciliation period in the fourth quarter of 2021. Shared savings payable for Episodes of Care Services included $6.8 million due to CMS as of December 31, 2020, the majority of which was settled with CMS in the first quarter of 2021. Shared savings payable included $36.6 million as of September 30, 2021 primarily related to the fourth reconciliation received in June 2021, which is expected to be paid to customers related to their portion of savings earned under the BPCI-A program. Additionally, there is $6.6 million included in shared savings payable at September 30, 2021, which represents amounts withheld from customers under the BPCI-A program based on contractual withholding percentages. This amount has been received by us from CMS and is held as restricted cash. We expect to remit these amounts to customers at the conclusion of the program, at which time both restricted cash and the liability will be reduced. (4) Contract liabilities in our Episodes of Care Services segment represent management’s estimate of savings amounts we expect to share with our customers based on contractual shared savings percentages related to the amounts we expect to be entitled to receive under the BPCI-A program for the next two reconciliation periods and service level agreements with certain customers. As of September 30, 2021, contract liabilities of $29.2 million cover episodes of care commencing in the period October 2020 through September 2021. These amounts offset the gross amount we expect to receive for the same period included in contract assets as of September 30, 2021. Contract liabilities in the Home & Community Services segment of $4.2 million as of September 30, 2021 represent management’s estimate of potential refund liabilities due to certain clients as a result of certain service levels not being achieved during the contractual periods primarily due to COVID-19. (5) Deferred revenue is included in other current liabilities on the Condensed Consolidated Balance Sheets and primarily relates to advance payments received from certain customers. The table below summarizes the activity recorded in the contract asset and liability accounts for the three and nine months ended September 30, 2021 and 2020. Three months ended September 30, Nine months ended September 30, Contract Assets 2021 2020 2021 2020 (in millions) (in millions) Balance at beginning of period $ 58.2 $ 50.9 $ 27.8 $ 38.3 Performance obligation completed, converted to accounts receivable — — (27.4) (43.9) Estimated revenue recognized related to performance obligations satisfied over time 36.4 59.1 94.2 115.6 Balance at end of period $ 94.6 $ 110.0 $ 94.6 $ 110.0 Three months ended September 30, Nine months ended September 30, Contract Liabilities 2021 2020 2021 2020 (in millions) (in millions) Balance at beginning of period $ 19.5 $ 8.3 $ 6.2 $ 3.1 Performance obligation completed, converted to shared savings payable — — (4.4) (4.6) Payments made to customer (0.1) — (0.7) — Estimated amounts due to customer related to performance obligations satisfied at a point-in-time 1.4 — 3.6 — Estimated amounts due to customer related to performance obligations satisfied over time 12.6 26.7 28.7 36.5 Balance at end of period $ 33.4 $ 35.0 $ 33.4 $ 35.0 Three months ended September 30, Nine months ended September 30, Deferred Revenue 2021 2020 2021 2020 (in millions) (in millions) Balance at beginning of period $ 4.4 $ 1.5 $ 3.8 $ 1.2 Payments received from customers 0.8 8.1 9.1 10.1 Revenue recognized upon completion of performance obligation (4.2) (3.5) (11.9) (5.2) Balance at end of period $ 1.0 $ 6.1 $ 1.0 $ 6.1 Three months ended September 30, Nine months ended September 30, Shared Savings Payable 2021 2020 2021 2020 (in millions) (in millions) Balance at beginning of period $ 54.2 $ 51.6 $ 80.8 $ 58.2 Amounts paid to customer and/or CMS (33.9) (26.7) (148.9) (94.6) Amounts due to customer upon completion of performance obligation 23.2 8.3 111.6 69.6 Balance at end of period $ 43.5 $ 33.2 $ 43.5 $ 33.2

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, net	Property and equipment, net were as follows as of each of the dates presented: September 30, 2021 December 31, 2020 (in millions) Computer equipment $ 19.1 $ 16.6 Leasehold Improvements 18.5 18.5 Furniture and fixtures 6.3 5.8 Software 2.5 2.4 Projects in progress 0.8 0.3 Property and equipment, gross 47.2 43.6 Less: Accumulated depreciation and amortization (24.2) (18.2) Property and equipment, net $ 23.0 $ 25.4

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets were as follows as of each of the dates presented: September 30, 2021 December 31, 2020 Estimated Useful Life (years) Gross Carrying Amount Accumulated amortization Net Carrying Value Gross Carrying Amount Accumulated amortization Net Carrying Value (in millions) Customer relationships 3 - 20 $ 530.5 $ (120.1) $ 410.4 $ 530.5 $ (92.9) $ 437.6 Acquired and capitalized software 3 - 6 140.7 (72.6) 68.1 123.6 (54.3) 69.3 Total $ 671.2 $ (192.7) $ 478.5 $ 654.1 $ (147.2) $ 506.9
Schedule of Expected Amortization Expense	Expected amortization expense as of September 30, 2021 related to intangible assets, including internal-use software development costs, was as follows: (in millions) Remainder of 2021 $ 15.7 2022 57.2 2023 52.6 2024 37.3 2025 33.9 thereafter 281.8 $ 478.5

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Change in Carrying Amount of Goodwill	The change in the carrying amount of goodwill for each reporting unit is as follows: Home & Community Services Episodes of Care Services Total (in millions) Balance at December 31, 2020 $ 170.4 $ 426.3 $ 596.7 Measurement period adjustments — 0.4 0.4 Balance at September 30, 2021 $ 170.4 $ 426.7 $ 597.1

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2021
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses consist of the following: September 30, December 31, 2021 2020 (in millions) Accrued payroll and payroll-related expenses $ 46.4 $ 47.1 Shared savings payable 43.5 80.8 Other accrued expenses 28.1 19.0 Accounts payable 6.4 0.7 Accrued income taxes 0.3 — Total accounts payable and accrued liabilities $ 124.7 $ 147.6

Long-Term Debt (Tables)

Long-Term Debt (Tables)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Schedule of Long-Term Debt	Long-term debt was as follows: September 30, December 31, 2021 2020 (in millions) Revolving Facility $ — $ — Term Loan — 272.5 2020 Incremental Term Loans — 140.0 2021 Term Loan 350.0 — Total debt 350.0 412.5 Unamortized debt issuance costs (6.3) (5.5) Unamortized discount on debt (4.8) (5.7) Total debt, net 338.9 401.3 Less current maturities (3.5) (4.2) Total long-term debt $ 335.4 $ 397.1
Future Principal Maturities of Long-Term Debt	The aggregate principal maturities of long-term debt due subsequent to September 30, 2021 are as follows: (in millions) Remainder of 2021 $ 0.9 2022 3.5 2023 3.5 2024 3.5 2025 3.5 Thereafter 335.1 $ 350.0

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	Assets and liabilities measured at fair value on a recurring basis were as follows: September 30, 2021 Balance Sheet Classification Type of Instrument Level 1 Level 2 Level 3 Total (in millions) Cash equivalents Money market funds $ 400.1 $ — $ — $ 400.1 Customer EAR liability Customer equity appreciation rights — — 80.4 80.4 Contingent consideration Consideration due to sellers — — 2.4 2.4 December 31, 2020 Balance Sheet Classification Type of Instrument Level 1 Level 2 Level 3 Total (in millions) Cash equivalents Money market funds $ 20.0 $ — $ — $ 20.0 Customer EAR liability Customer equity appreciation rights — — 21.6 21.6 Contingent consideration Consideration due to sellers — — 15.2 15.2
Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis	The changes in Level 3 liabilities measured at fair value on a recurring basis were as follows: Contingent Consideration Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 (in millions) (in millions) Beginning of period $ 2.4 $ 40.0 $ 15.2 $ 39.8 Payment of contingent consideration — (40.0) (15.0) (40.0) Remeasurement of contingent consideration included in selling, general and administrative expense — — 2.2 0.2 Balance at September 30, $ 2.4 $ — $ 2.4 $ — Customer equity appreciation rights Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 (in millions) (in millions) Beginning of period $ 102.7 $ 3.2 $ 21.6 $ — Grant date fair value estimate recorded as reduction to revenue 5.0 4.9 14.8 7.5 Remeasurement of fair value included in other expense (income), net (27.3) 6.3 44.0 6.9 Balance at September 30, $ 80.4 $ 14.4 $ 80.4 $ 14.4
Schedule of Valuation Techniques and Significant Unobservable Inputs	The valuation techniques and significant unobservable inputs used in recurring Level 3 fair value measurements were as follows as of September 30, 2021: Fair Value (in millions) Valuation Technique Significant Unobservable Inputs Assumption Customer equity appreciation rights $ 80.4 Monte Carlo Volatility 45.0% Dividend yield 0% Risk-free rate 0.53% Expected term (years) 3 Fair Value Valuation Technique Significant Unobservable Inputs Discount Rate Consideration due to sellers $ 2.4 Discounted approach Discount Rate 5.0% The valuation techniques and significant unobservable inputs used in recurring Level 3 fair value measurements were as follows as of December 31, 2020: Fair Value (in millions) Valuation Technique Significant Unobservable Inputs Assumption Customer equity appreciation rights $ 21.6 Monte Carlo Volatility 55.0% Dividend yield 0% Risk-free rate 0.11% Expected term (years) 1.35 Fair Value Valuation Technique Significant Unobservable Inputs Discount Rate Consideration due to sellers $ 15.2 Discounted approach Discount Rate 5.0%

Noncontrolling Interest (Tables

Noncontrolling Interest (Tables)	9 Months Ended
	Sep. 30, 2021
Noncontrolling Interest [Abstract]
Summary of Ownership Interests in Cure TopCo	The following table summarizes the ownership interests in Cure TopCo as of September 30, 2021: LLC Units Ownership Percentage Number of LLC Units held by Signify Health, Inc. 170,355,960 75.1% Number of LLC Units held by noncontrolling interests 56,482,324 24.9% Total LLC Units outstanding 226,838,284 100.0%

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Schedule of Earnings (Loss) Per Share	The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted earnings (loss) per share of Class A common stock for the three and nine months ended September 30, 2021. The basic and diluted earnings (loss) per share for the nine months ended September 30, 2021 represents only the period from February 12, 2021 to September 30, 2021, which represents the period wherein we had outstanding Class A common stock. Three months ended September 30, 2021 Nine months ended September 30, 2021 (in millions) Net income (loss) $ 29.3 $ (22.5) Less: Net income (loss) attributable to pre-Reorganization Transactions — (17.2) Less: Net income (loss) attributable to the noncontrolling interest 9.1 (2.3) Net income (loss) attributable to Signify Health, Inc. $ 20.2 $ (3.0) Weighted average shares of Class A common stock outstanding - Basic 169,055,078 167,905,136 Dilutive Shares: Stock Options 3,332,831 — RSUs 46,041 — LLC Units — — Total Dilutive shares 3,378,872 — Weighted average shares of Class A common stock outstanding - Diluted 172,433,950 167,905,136 Earnings (loss) per share of Class A common stock - Basic $ 0.12 $ (0.02) Earnings (loss) per share of Class A common stock - Diluted $ 0.12 $ (0.02)
Schedule of Antidilutive Shares Outstanding Excluded from Computation of Diluted Earnings Per Share	The following table summarizes the stock options, RSUs, and weighted-average LLC Units that were anti-dilutive for the periods indicated. As a result, these shares, which were outstanding, were excluded from the computation of diluted earnings per share for the periods indicated: Three months ended September 30, 2021 Nine months ended September 30, 2021 Antidilutive Shares: Stock Options 1,294,305 5,302,839 RSUs 149,539 290,419 LLC Units 58,713,929 58,713,929

Commitment and Contingencies (T

Commitment and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Summary of SEU Activity	The following table summarizes the change in the SEU liability: Three months ended September 30, 2021 Nine months ended September 30, 2021 (in millions) Balance at beginning of period $ 0.7 $ — SEU expense included in service expense — 0.6 SEU expense included in SG&A expense 0.2 1.4 Cash payments (0.2) (1.3) Balance at end of period $ 0.7 $ 0.7

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Schedule of Operating Segment Results	Our operating segment results for the periods presented were as follows: Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 (in millions) (in millions) Revenue Home & Community Services $ 169.1 $ 114.7 $ 496.9 $ 301.8 Episodes of Care Services 30.1 40.0 95.1 115.3 Segment Adjusted EBITDA Home & Community Services 49.9 20.8 146.8 65.8 Episodes of Care Services (7.9) 7.9 (15.8) 20.2 Less: reconciling items to net loss: Unallocated costs (1) (15.5) 20.9 88.1 38.5 Depreciation and amortization 17.6 15.8 51.6 46.0 Interest expense 4.2 5.1 17.5 16.2 Loss before income taxes $ 35.7 $ (13.1) $ (26.2) $ (14.7) (1) Unallocated costs as follows: Other (income) expense, net (2) (27.4) 6.3 43.6 6.9 Loss on Debt Extinguishment — — 5.0 — Equity-based compensation 3.7 2.1 9.5 10.0 SEU Expense 0.2 — 2.0 — Customer equity appreciation rights 5.0 4.9 14.8 7.5 Transaction-related expenses 2.9 6.8 9.5 10.8 Non-allocated costs (3) 0.1 0.8 3.7 3.3 Total unallocated costs $ (15.5) $ 20.9 $ 88.1 $ 38.5 (2) Other (income) expense, net includes the remeasurement of the fair value of the outstanding customer EAR. (3) Non-allocated costs included remeasurement of contingent consideration, management fees paid to our capital partner and certain non-recurring expenses, including those associated with the closure of certain facilities, the sale of certain assets, one-time expenses related to the COVID-19 pandemic and the early termination of certain contracts. These costs are not considered by our Chief Operating Decision Maker in making resource allocation decisions.

Nature of Operations (Details)

Nature of Operations (Details) $ / shares in Units, $ in Millions	Feb. 16, 2021USD ($)vote$ / sharesshares	Sep. 30, 2021segmentvoteclass
Subsidiary, Sale of Stock [Line Items]
Number of operating segments | segment		2
Number of classes of non-voting common units | class		1
Number of classes of common stock | class		2
Number of votes per share | vote	1
Cure TopCo
Subsidiary, Sale of Stock [Line Items]
Economic ownership interest by parent (as a percent)	74.10%	75.10%
Economic ownership interest by noncontrolling interest (as a percent)	25.90%	24.90%
Class A Common Stock
Subsidiary, Sale of Stock [Line Items]
Number of votes per share | vote		1
IPO
Subsidiary, Sale of Stock [Line Items]
Gross proceeds from IPO	$ 648.6
Net proceeds from IPO	609.7
Underwriting discounts and commissions	$ 38.9
IPO | Class A Common Stock
Subsidiary, Sale of Stock [Line Items]
Sale of stock, number of shares issued in transaction (in shares) | shares	27,025,000
Sale of stock, price per share (in dollars per share) | $ / shares	$ 24
Over-Allotment Option | Class A Common Stock
Subsidiary, Sale of Stock [Line Items]
Sale of stock, number of shares issued in transaction (in shares) | shares	3,525,000

Significant Accounting Polici_4

Significant Accounting Policies - Narrative (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)segment	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Cash and Cash Equivalents [Line Items]
Number of operating segments | segment			2
Return of funds following conclusion of effective period of CMS master agreement, period			18 months
Restricted cash	$ 7.1		$ 7.1		$ 4.4
Allowance for doubtful accounts	7.8		7.8		5.1
Advertising and marketing costs	0.4	$ 0.1	0.9	$ 1.2
PatientBlox
Cash and Cash Equivalents [Line Items]
Restricted cash	0		0		0.4
Secondary Repayment Source
Cash and Cash Equivalents [Line Items]
Restricted cash	0.5		0.5		0.5
Holding Pool
Cash and Cash Equivalents [Line Items]
Restricted cash	$ 6.6		$ 6.6		$ 3.5

Significant Accounting Polici_5

Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Cash and cash equivalents	$ 678.8	$ 72.6
Restricted cash	7.1	4.4
Total cash, cash equivalents, and restricted cash	$ 685.9	$ 77	$ 92.3	$ 50.2

Variable Interest Entities - Na

Variable Interest Entities - Narrative (Details) $ in Millions	Sep. 30, 2021USD ($)physicianPractice	Dec. 31, 2020USD ($)physicianPractice
Variable Interest Entity [Line Items]
Number of physician practices | physicianPractice	7	1
Assets	$ 2,126.5	$ 1,522.3
Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Assets	$ 18	$ 1.8

Variable Interest Entities - Sc

Variable Interest Entities - Schedule of Variable Interest Entities (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 678.8	$ 72.6
Accounts receivable, net	169.2	270.6
Total current assets	967.4	389.2
Total assets	2,126.5	1,522.3
Current liabilities
Accounts payable and accrued expenses	124.7	147.6
Total current liabilities	174.3	189.6
Total liabilities	667	628.3
Company capital	1,100.1
Retained earnings (accumulated deficit)	(3)
Total liabilities and stockholders' / members' equity	2,126.5	1,522.3
Variable Interest Entity, Primary Beneficiary
Current assets
Cash and cash equivalents	3.7	1.8
Accounts receivable, net	14.3	0
Total current assets	18	1.8
Total assets	18	1.8
Current liabilities
Accounts payable and accrued expenses	0.3	0.1
Total current liabilities	0.3	0.1
Total liabilities	0.3	0.1
Company capital	18.8	(0.7)
Retained earnings (accumulated deficit)	(1.1)	2.4
Total equity	17.7	1.7
Total liabilities and stockholders' / members' equity	$ 18	$ 1.8

Revenue Recognition - Narrative

Revenue Recognition - Narrative (Details)	9 Months Ended
	Sep. 30, 2021segment
Revenue from Contract with Customer [Abstract]
Number of operating segments	2

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disaggregation of Revenue [Line Items]
Revenue	$ 199.2	$ 154.7	$ 592	$ 417.1
Home & Community Services
Disaggregation of Revenue [Line Items]
Revenue	169.1	114.7	496.9	301.8
Episodes of Care Services
Disaggregation of Revenue [Line Items]
Revenue	30.1	40	95.1	115.3
Evaluations | Home & Community Services
Disaggregation of Revenue [Line Items]
Revenue	167.1	112.5	490.6	294.9
Other | Home & Community Services
Disaggregation of Revenue [Line Items]
Revenue	2	2.2	6.3	6.9
Other | Episodes of Care Services
Disaggregation of Revenue [Line Items]
Revenue	2.3	2.5	6.6	8.1
Episodes | Episodes of Care Services
Disaggregation of Revenue [Line Items]
Revenue	$ 27.8	$ 37.5	$ 88.5	$ 107.2

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Related Balance Sheets Account (Details) - USD ($) $ in Millions	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Dec. 31, 2019
ASSETS
Accounts receivable, net	$ 169.2		$ 270.6
Contract assets	94.6	$ 58.2	27.8	$ 110	$ 50.9	$ 38.3
Liabilities
Shared savings payable	43.5	54.2	80.8	33.2	51.6	58.2
Contract liabilities	33.4	19.5	6.2	35	8.3	3.1
Deferred revenue	1	$ 4.4	3.8	$ 6.1	$ 1.5	$ 1.2
Third Reconciliation Period of BPCI-A Program
Liabilities
Shared savings payable	36.6
Amounts Withheld Under BPCI-A Program
Liabilities
Shared savings payable	6.6
Episodes of Care Services
ASSETS
Accounts receivable, net	33.2		183.3
Contract assets	94.6		27.8
Liabilities
Shared savings payable	43.5		80.8
Contract liabilities	29.2		4.8
Deferred revenue	0.1		2.4
Episodes of Care Services | Centers for Medicare and Medicaid Services
ASSETS
Accounts receivable, net	4.6
Liabilities
Shared savings payable	0.3		6.8
Home & Community Services
ASSETS
Accounts receivable, net	136		87.3
Contract assets	0		0
Liabilities
Shared savings payable	0		0
Contract liabilities	4.2		1.4
Deferred revenue	$ 0.9		$ 1.4

Revenue Recognition - Contract

Revenue Recognition - Contract Assets (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Contract with Customer, Asset [Roll Forward]
Beginning balance	$ 58.2	$ 50.9	$ 27.8	$ 38.3
Performance obligation completed, converted to accounts receivable	0	0	(27.4)	(43.9)
Estimated revenue recognized related to performance obligations satisfied over time	36.4	59.1	94.2	115.6
Ending balance	$ 94.6	$ 110	$ 94.6	$ 110

Revenue Recognition - Contrac_2

Revenue Recognition - Contract Liabilities (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Contract with Customer, Refund Liability [Roll Forward]
Beginning balance	$ 19.5	$ 8.3	$ 6.2	$ 3.1
Performance obligation completed, converted to shared savings payable	0	0	(4.4)	(4.6)
Payments made to customer	(0.1)	0	(0.7)	0
Estimated amounts due to customer related to performance obligations satisfied at a point-in-time	1.4	0	3.6	0
Estimated amounts due to customer related to performance obligations satisfied over time	12.6	26.7	28.7	36.5
Ending balance	$ 33.4	$ 35	$ 33.4	$ 35

Revenue Recognition - Deferred

Revenue Recognition - Deferred Revenue (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Contract with Customer, Liability [Roll Forward]
Beginning balance	$ 4.4	$ 1.5	$ 3.8	$ 1.2
Payments received from customers	0.8	8.1	9.1	10.1
Revenue recognized upon completion of performance obligation	(4.2)	(3.5)	(11.9)	(5.2)
Ending balance	$ 1	$ 6.1	$ 1	$ 6.1

Revenue Recognition - Shared Sa

Revenue Recognition - Shared Savings Payable (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Shared Savings Payable [Roll Forward]
Beginning balance	$ 54.2	$ 51.6	$ 80.8	$ 58.2
Amounts paid to customer and/or CMS	(33.9)	(26.7)	(148.9)	(94.6)
Amounts due to customer upon completion of performance obligation	23.2	8.3	111.6	69.6
Ending balance	$ 43.5	$ 33.2	$ 43.5	$ 33.2

Property and Equipment - Proper

Property and Equipment - Property and Equipment, net (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 47.2	$ 43.6
Less: Accumulated depreciation and amortization	(24.2)	(18.2)
Property and equipment, net	23	25.4
Computer equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	19.1	16.6
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	18.5	18.5
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	6.3	5.8
Software
Property, Plant and Equipment [Line Items]
Property and equipment, gross	2.5	2.4
Projects in progress
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 0.8	$ 0.3

Property and Equipment - Narrat

Property and Equipment - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Depreciation	$ 2,100,000	$ 1,800,000	$ 6,200,000	$ 5,500,000
Impairment of property and equipment	$ 0	$ 0	$ 0	$ 0

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 671.2	$ 654.1
Accumulated amortization	(192.7)	(147.2)
Net Carrying Value	478.5	506.9
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	530.5	530.5
Accumulated amortization	(120.1)	(92.9)
Net Carrying Value	$ 410.4	437.6
Customer relationships | Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (years)	3 years
Customer relationships | Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (years)	20 years
Acquired and capitalized software
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 140.7	123.6
Accumulated amortization	(72.6)	(54.3)
Net Carrying Value	$ 68.1	$ 69.3
Acquired and capitalized software | Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (years)	3 years
Acquired and capitalized software | Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (years)	6 years

Intangible Assets - Narrative (

Intangible Assets - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Capitalization of internally-developed software costs	$ 5,500,000	$ 5,500,000	$ 17,100,000	$ 15,700,000
Impairment of finite-lived intangible assets	0	0	0	0
Amortization of intangible assets	$ 15,500,000	$ 14,000,000	$ 45,400,000	$ 40,500,000

Intangible Assets - Schedule _2

Intangible Assets - Schedule of Expected Amortization Expense (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Remainder of 2021	$ 15.7
2022	57.2
2023	52.6
2024	37.3
2025	33.9
thereafter	281.8
Net Carrying Value	$ 478.5	$ 506.9

Goodwill - Change in Carrying A

Goodwill - Change in Carrying Amount of Goodwill (Details) $ in Millions	9 Months Ended
	Sep. 30, 2021USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 596.7
Measurement period adjustments	0.4
Ending balance	597.1
Home & Community Services
Goodwill [Roll Forward]
Beginning balance	170.4
Measurement period adjustments	0
Ending balance	170.4
Episodes of Care Services
Goodwill [Roll Forward]
Beginning balance	426.3
Measurement period adjustments	0.4
Ending balance	$ 426.7

Goodwill - Narrative (Details)

Goodwill - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill impairment	$ 0	$ 0	$ 0	$ 0

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Millions	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Accrued payroll and payroll-related expenses	$ 46.4		$ 47.1
Shared savings payable	43.5	$ 54.2	80.8	$ 33.2	$ 51.6	$ 58.2
Other accrued expenses	28.1		19
Accounts payable	6.4		0.7
Accrued income taxes	0.3		0
Total accounts payable and accrued liabilities	$ 124.7		$ 147.6

Long-Term Debt - Schedule of Lo

Long-Term Debt - Schedule of Long-Term Debt (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Total debt	$ 350	$ 412.5
Unamortized debt issuance costs	(6.3)	(5.5)
Unamortized discount on debt	(4.8)	(5.7)
Total debt, net	338.9	401.3
Less current maturities	(3.5)	(4.2)
Total long-term debt	335.4	397.1
Credit Agreement | Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Total debt	0	0
Credit Agreement | Secured Debt
Debt Instrument [Line Items]
Total debt	0	272.5
2020 Incremental Term Loans | Secured Debt
Debt Instrument [Line Items]
Total debt	0	140
2021 Term Loan | Secured Debt
Debt Instrument [Line Items]
Total debt	$ 350	$ 0

Long-Term Debt - Narrative (Det

Long-Term Debt - Narrative (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Debt Disclosure [Abstract]
Proceeds from lines of credit	$ 77,000,000
Debt Instrument [Line Items]
Loss on extinguishment of debt		$ 0	$ 0	$ 5,000,000	$ 0
Credit Agreement, Term Loan | Secured Debt
Debt Instrument [Line Items]
Effective interest rate (as a percent)		3.75%		3.75%		5.50%
Credit Agreement, Incremental Term Loan | Secured Debt
Debt Instrument [Line Items]
Effective interest rate (as a percent)						6.25%
2021 Term Loan | Secured Debt
Debt Instrument [Line Items]
Debt instrument, face amount		$ 350,000,000		$ 350,000,000
Amortization payments (as a percent)		0.25%		0.25%
Revolving Facility | Revolving Credit Facility
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity		$ 185,000,000		$ 185,000,000
Credit Agreement
Debt Instrument [Line Items]
Loss on extinguishment of debt		$ 0		$ 5,000,000
Maximum net leverage ratio		4.50		4.50
Total amount revolving credit commitments (as a percent)		35.00%		35.00%
Credit Agreement | Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Remaining borrowing capacity		$ 172,800,000		$ 172,800,000

Long-Term Debt - Future Princip

Long-Term Debt - Future Principal Maturities of Long-Term Debt (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Long-term Debt, Fiscal Year Maturity [Abstract]
Remainder of 2021	$ 0.9
2022	3.5
2023	3.5
2024	3.5
2025	3.5
Thereafter	335.1
Total debt	$ 350	$ 412.5

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Customer EAR liability	$ 80.4	$ 21.6
Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	400.1	20
Customer EAR liability	80.4	21.6
Contingent consideration	2.4	15.2
Level 1 | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	400.1	20
Customer EAR liability	0	0
Contingent consideration	0	0
Level 2 | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Customer EAR liability	0	0
Contingent consideration	0	0
Level 3 | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Customer EAR liability	80.4	21.6
Contingent consideration	$ 2.4	$ 15.2

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Contingent Consideration and Customer Equity Appreciation Rights (Details) - Level 3 - Fair Value, Recurring - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Contingent Consideration
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 2.4	$ 40	$ 15.2	$ 39.8
Payment of contingent consideration	0	(40)	(15)	(40)
Remeasurement of fair value	0	0	2.2	0.2
Ending balance	2.4	0	2.4	0
Customer equity appreciation rights
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	102.7	3.2	21.6	0
Ending balance	80.4	14.4	80.4	14.4
Customer equity appreciation rights | Revenue from Contract with Customer, Excluding Assessed Tax
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Remeasurement of fair value	5	4.9	14.8	7.5
Customer equity appreciation rights | Other Nonoperating Income (Expense)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Remeasurement of fair value	$ (27.3)	$ 6.3	$ 44	$ 6.9

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Valuation Techniques and Significant Unobservable Inputs (Details) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2021USD ($)	Dec. 31, 2020USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Customer equity appreciation rights, fair value	$ 80.4	$ 21.6
Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Customer equity appreciation rights, fair value	80.4	21.6
Consideration due to sellers, fair value	2.4	15.2
Level 3 | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Customer equity appreciation rights, fair value	80.4	21.6
Consideration due to sellers, fair value	2.4	15.2
Level 3 | Fair Value, Recurring | Valuation Technique, Monte Carlo
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Customer equity appreciation rights, fair value	$ 80.4	$ 21.6
Level 3 | Fair Value, Recurring | Valuation Technique, Monte Carlo | Volatility
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Customer equity appreciation rights, measurement input	0.450	0.550
Level 3 | Fair Value, Recurring | Valuation Technique, Monte Carlo | Dividend Yield
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Customer equity appreciation rights, measurement input	0	0
Level 3 | Fair Value, Recurring | Valuation Technique, Monte Carlo | Risk-free rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Customer equity appreciation rights, measurement input	0.0053	0.0011
Level 3 | Fair Value, Recurring | Valuation Technique, Monte Carlo | Expected term (years)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Customer equity appreciation rights, term	3 years	1 year 4 months 6 days
Level 3 | Fair Value, Recurring | Valuation Technique, Discounted Cash Flow
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Consideration due to sellers, fair value	$ 2.4	$ 15.2
Level 3 | Fair Value, Recurring | Valuation Technique, Discounted Cash Flow | Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Consideration due to sellers, measurement input	0.050	0.050

Shareholders' Equity (Details)

Shareholders' Equity (Details) $ / shares in Units, $ in Millions	Feb. 16, 2021USD ($)vote$ / sharesshares	Sep. 30, 2021voteclass
Class of Stock [Line Items]
Number of classes of common stock | class		2
Number of votes per share | vote	1
IPO
Class of Stock [Line Items]
Gross proceeds from IPO | $	$ 648.6
Net proceeds from IPO | $	609.7
Underwriting discounts and commissions | $	$ 38.9
Class A Common Stock
Class of Stock [Line Items]
Number of votes per share | vote		1
Class A Common Stock | IPO
Class of Stock [Line Items]
Sale of stock, number of shares issued in transaction (in shares) | shares	27,025,000
Sale of stock, price per share (in dollars per share) | $ / shares	$ 24
Class A Common Stock | Over-Allotment Option
Class of Stock [Line Items]
Sale of stock, number of shares issued in transaction (in shares) | shares	3,525,000
Class B Common Stock
Class of Stock [Line Items]
Number of votes per share | vote		1

Noncontrolling Interest (Detail

Noncontrolling Interest (Details) - shares	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021	Feb. 16, 2021
LLC Units Exchanged for Shares of Class A Common Stock
Ownership Percentage
Units exchanged (in shares)	1,748,451	1,748,451
Cure TopCo
Ownership Percentage
Number of LLC Units held by Signify Health, Inc. (as a percent)	75.10%	75.10%	74.10%
Number of LLC Units held by non-controlling interests (as a percent)	24.90%	24.90%	25.90%
Total LLC Units outstanding (as a percent)	100.00%	100.00%
Cure TopCo
LLC Units
LLC Units (in shares)	226,838,284	226,838,284
Cure TopCo | Parent
LLC Units
LLC Units (in shares)	170,355,960	170,355,960
Cure TopCo | Non-controlling interest
LLC Units
LLC Units (in shares)	56,482,324	56,482,324

Equity-Based Compensation (Deta

Equity-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Jan. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)	4,985,782		4,985,782
Weighted average exercise price (in dollars per share)	$ 6.07		$ 6.07
Incentive Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation	$ 1.5	$ 1.7	$ 4.4	$ 8.7
Units outstanding (in shares)	13,555,806		13,555,806
Units outstanding (in shares)	8,208,887		8,208,887
Incentive Units | Selling, General and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation	$ 1.4	1.6	$ 4.3	8.6
Incentive Units | Service Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation	$ 0.1	0.1	$ 0.1	0.1
Incentive Units, Performance-based
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Units outstanding (in shares)	5,977,283		5,977,283
Total unrecognized compensation expense	$ 13.2		$ 13.2
Incentive Units, Time-based
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average recognition period			9 months 18 days
Total unrecognized compensation expense	$ 6.9		$ 6.9
Share-based Payment Arrangement, Performance Based Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)	977,248		977,248
Total unrecognized compensation expense	$ 2.1		$ 2.1
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation	$ 0.3	0.4	1	1.3
Share-based Payment Arrangement, Time-based Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation			$ 2.2
Weighted average recognition period			10 months 24 days
2021 LTIP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in shares authorized (as a percent)			3.00%
Options outstanding (in shares)	1,294,305		1,294,305
Weighted average exercise price (in dollars per share)	$ 25.01		$ 25.01
Unrecognized compensation expense	$ 19.6		$ 19.6
Weighted average recognition period			1 year 6 months
2021 LTIP | Management
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options issued in period (in shares)	335,355		1,368,805
Weighted average exercise price (in dollars per share)	$ 27.21		$ 25.04
Total grant date fair value			$ 16.8
2021 LTIP | RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Units outstanding (in shares)	290,419		290,419
2021 LTIP | RSUs | Board of Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			1 year
Grants in period (in shares)	155,039		306,919
Grant date fair value of award			$ 8
2021 LTIP | RSUs | Board of Directors | Selling, General and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation	$ 0.8		$ 1.5
2021 LTIP | RSUs | Board of Directors | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			4 years
2021 LTIP | Stock Options | Management | Selling, General and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation	$ 1.1		$ 2.6
2021 LTIP | Stock Options | Management | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
2021 LTIP | Stock Options | Management | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			4 years
ESPP | Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in shares authorized (as a percent)			1.00%
ESPP | Employee Stock | Selling, General and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation		$ 0.2		$ 0.2
Class A Common Stock | 2021 LTIP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for issuance (in shares)					16,556,298
Number of additional shares authorized (in shares)			14,191,113
Class A Common Stock | ESPP | Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for issuance (in shares)					4,730,371
Number of additional shares authorized (in shares)			4,730,371

Earnings (Loss) Per Share - Sch

Earnings (Loss) Per Share - Schedule of Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, $ in Millions		2 Months Ended	3 Months Ended		8 Months Ended	9 Months Ended
		Feb. 15, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Net income (loss)		$ (17.2)	$ 29.3	$ (13.3)	$ (5.3)	$ (22.5)	$ (15.2)
Less: Net income (loss) attributable to the noncontrolling interest			9.1		(2.3)
Net income (loss) attributable to parent		$ (17.2)	$ 20.2	$ (13.3)	$ (3)		$ (15.2)
Weighted average shares of Class A common stock outstanding - Basic (in shares)	[1]		169,055,078			167,905,136
Dilutive Shares:
Total Dilutive shares (in shares)			3,378,872			0
Weighted average shares of Class A common stock outstanding, diluted (in shares)	[1]		172,433,950			167,905,136
Earnings (loss) per share of Class A common stock - Basic (in dollars per share)	[1]		$ 0.12			$ (0.02)
Earnings (loss) per share of Class A common stock - Diluted (in dollars per share)	[1]		$ 0.12			$ (0.02)
Stock Options
Dilutive Shares:
Dilutive shares (in shares)			3,332,831			0
RSUs
Dilutive Shares:
Dilutive shares (in shares)			46,041			0
LLC Units
Dilutive Shares:
Dilutive shares (in shares)			0			0
[1]	(1)Basic and diluted net loss per share of Class A common stock is applicable only for the periods subsequent to February 12, 2021, which is the period following the initial public offering ("IPO") and related Reorganization Transactions (as defined in Note 1 to the Unaudited Condensed Consolidated Financial Statements). See Note 15 for the basis for the computation of net earnings (loss) per share.

Earnings (Loss) Per Share - Ant

Earnings (Loss) Per Share - Anti-Dilutive Shares (Details) - shares	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	1,294,305	5,302,839
RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	149,539	290,419
LLC Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	58,713,929	58,713,929
Performance Based Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	977,247
Performance Based LLC Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	5,977,283

Transaction-related Expenses (D

Transaction-related Expenses (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Subsidiary, Sale of Stock [Line Items]
Transaction-related expenses, corporate development activities	$ 2.9	$ 5.9	$ 4.8	$ 9.9
Transaction-related expenses	$ 2.9	6.8	9.5	10.8
IPO
Subsidiary, Sale of Stock [Line Items]
Transaction-related expenses		$ 0.9	$ 4.7	$ 0.9

Commitment and Contingencies -

Commitment and Contingencies - Narrative (Details) $ in Millions	1 Months Ended				9 Months Ended
	May 31, 2021USD ($)	Feb. 28, 2021	Sep. 30, 2020USD ($)	Dec. 31, 2019USD ($)	Sep. 30, 2021USD ($)letterOfCreditshares	Oct. 01, 2021USD ($)renewal	Jun. 30, 2021USD ($)	Dec. 31, 2020USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding letters of credit					$ 9.2
Sales tax reserve liability					3.8			$ 8
Contingent consideration, noncurrent					0			2.1
Contingent consideration, current					2.4			13.1
Payments for contingent consideration	$ 15
Oklahoma City, OK
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of lease renewal options | renewal						2
Subsequent Event | Oklahoma City, OK
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lease term						7 years 3 months
Lease renewal term						5 years
Total lease payments						$ 4.2
Related Reciprocal Letter of Credit Provided
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding letters of credit					$ 8.8
Number of related letters of credit | letterOfCredit					3
Customer equity appreciation rights | Share-based Payment Arrangement, Nonemployee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award requisite service period			2 years 6 months	3 years
Expiration period of award				20 years
Grant date fair value			$ 36.6	$ 15.2
Original grant date fair value unrecognized					$ 24.6
Performance period of award					1 year 3 months
Synthetic Equity Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Original grant date fair value unrecognized					$ 0.7		$ 0.7	$ 0
Weighted average price volume period		30 days
Synthetic Equity Units, Time-Based Vesting
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Units outstanding (in shares) | shares					446,880
Synthetic Equity Units, Performance-Based Vesting
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Units outstanding (in shares) | shares					119,623

Commitment and Contingencies _2

Commitment and Contingencies - Summary of SEU Activity (Details) - Synthetic Equity Units - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount [Roll Forward]
Beginning balance	$ 0.7	$ 0
Cash payments	(0.2)	(1.3)
Ending balance	0.7	0.7
Service Expense
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount [Roll Forward]
SEU expense	0	0.6
Selling, General and Administrative Expenses
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount [Roll Forward]
SEU expense	$ 0.2	$ 1.4

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	Feb. 16, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Feb. 28, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income tax expense (benefit)		$ 6.4	$ 0.2	$ (3.7)	$ 0.5
Effective tax rate (as a percent)		18.00%		13.90%
Deferred tax asset	$ 29				$ 0
Net operating loss carryforwards							$ 6.2
Maximum reduction of taxable income (as a percent)							80.00%
Applicable cash savings payable (as a percent)						85.00%
Applicable cash savings retainable (as a percent)						15.00%
Tax receivable agreement liability		$ 59.6		$ 59.6			$ 0
Increase in tax receivable agreement liability		$ 8.3

Segment Reporting - Narrative (

Segment Reporting - Narrative (Details)	9 Months Ended
	Sep. 30, 2021segment
Segment Reporting [Abstract]
Number of reportable segments	2

Segment Reporting - Schedule of

Segment Reporting - Schedule of Operating Segment Results (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Segment Reporting Information [Line Items]
Revenue	$ 199.2	$ 154.7	$ 592	$ 417.1
Less: reconciling items to net loss:
Unallocated costs	(15.5)	20.9	88.1	38.5
Depreciation and amortization	17.6	15.8	51.6	46
Interest expense	4.2	5.1	17.5	16.2
Income (loss) before income taxes	35.7	(13.1)	(26.2)	(14.7)
Unallocated costs as follows:
Other (income) expense	(27.4)	6.3	43.6	6.9
Loss on Debt Extinguishment	0	0	5	0
Transaction-related expenses	2.9	6.8	9.5	10.8
Non-allocated costs	0.1	0.8	3.7	3.3
Total unallocated costs	(15.5)	20.9	88.1	38.5
Equity-based compensation
Unallocated costs as follows:
Equity-based compensation	3.7	2.1	9.5	10
SEU Expense
Unallocated costs as follows:
Equity-based compensation	0.2	0	2	0
Customer equity appreciation rights
Unallocated costs as follows:
Equity-based compensation	5	4.9	14.8	7.5
Home & Community Services
Segment Reporting Information [Line Items]
Revenue	169.1	114.7	496.9	301.8
Home & Community Services | Operating Segments
Segment Reporting Information [Line Items]
Revenue	169.1	114.7	496.9	301.8
Segment Adjusted EBITDA	49.9	20.8	146.8	65.8
Episodes of Care Services
Segment Reporting Information [Line Items]
Revenue	30.1	40	95.1	115.3
Episodes of Care Services | Operating Segments
Segment Reporting Information [Line Items]
Revenue	30.1	40	95.1	115.3
Segment Adjusted EBITDA	$ (7.9)	$ 7.9	$ (15.8)	$ 20.2

Concentrations (Details)

Concentrations (Details) - Customer Concentration Risk	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Revenue from Contract with Customer Benchmark | Customer One
Concentration Risk [Line Items]
Concentration risk (as a percent)	21.00%	25.00%
Revenue from Contract with Customer Benchmark | Customer Two
Concentration Risk [Line Items]
Concentration risk (as a percent)	24.00%	24.00%
Revenue from Contract with Customer Benchmark | Customer Three
Concentration Risk [Line Items]
Concentration risk (as a percent)	12.00%	12.00%
Revenue from Contract with Customer Benchmark | Customer Four
Concentration Risk [Line Items]
Concentration risk (as a percent)	12.00%
Revenue from Contract with Customer Benchmark | Top Ten Customers
Concentration Risk [Line Items]
Concentration risk (as a percent)	77.00%	78.00%
Revenue from Contract with Customer Benchmark | Centers for Medicare and Medicaid Services
Concentration Risk [Line Items]
Concentration risk (as a percent)	13.00%	14.00%
Accounts Receivable | Customer One
Concentration Risk [Line Items]
Concentration risk (as a percent)		18.00%
Accounts Receivable | Customer Two
Concentration Risk [Line Items]
Concentration risk (as a percent)		15.00%
Accounts Receivable | Customer Three
Concentration Risk [Line Items]
Concentration risk (as a percent)		13.00%
Accounts Receivable | Customer Four
Concentration Risk [Line Items]
Concentration risk (as a percent)		10.00%
Accounts Receivable | Centers for Medicare and Medicaid Services
Concentration Risk [Line Items]
Concentration risk (as a percent)		3.00%

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ in Millions	Mar. 07, 2019	Sep. 30, 2020	Sep. 30, 2020
Former Director | Consulting Agreement, Annual Compensation
Related Party Transaction [Line Items]
Related party transaction, amounts of transaction	$ 0.3
Former Director | Consulting Agreement, Deal Consideration
Related Party Transaction [Line Items]
Related party transaction, amounts of transaction	$ 10
Cash transaction fee (as a percent)	3.00%
Former Director | Consulting Agreement, Incremental Deal Consideration
Related Party Transaction [Line Items]
Cash transaction fee (as a percent)	1.50%
Director | Letter Agreement
Related Party Transaction [Line Items]
Related party transaction, amounts of transaction		$ 0.1	$ 0.2

Uncategorized Items - sgfy-2021

Label	Element	Value
Stock Issued and Granted During Period, Value	sgfy_StockIssuedAndGrantedDuringPeriodValue	$ 8,800,000
Stock Issued During Period, Value, Effect of Reorganization Transactions	sgfy_StockIssuedDuringPeriodValueEffectOfReorganizationTransactions	0
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	604,900,000
Stock Issued During Period, Value, Stock Options Exercised	us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised	2,700,000
Adjustments to Additional Paid in Capital, Contributions	sgfy_AdjustmentsToAdditionalPaidInCapitalContributions	26,000,000
Stock Issued During Period, Value, Conversion of Convertible Securities	us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0
Adjustments to Additional Paid in Capital, Deferred Tax Adjustment	sgfy_AdjustmentsToAdditionalPaidInCapitalDeferredTaxAdjustment	6,300,000
Limited Liability Company (LLC) Members' Equity, Unit-based Payment Arrangement	us-gaap_LimitedLiabilityCompanyLLCMembersEquityUnitBasedCompensation	900,000
Adjustments to Additional Paid in Capital, Tax Receivable Agreement Liability and Deferred Taxes Arising from LLC Interest Ownership Exchanges	sgfy_AdjustmentsToAdditionalPaidInCapitalTaxReceivableAgreementLiabilityAndDeferredTaxesArisingFromLLCInterestOwnershipExchanges	400,000
Adjustments to Additional Paid in Capital, Subscription Fee Receivable	sgfy_AdjustmentsToAdditionalPaidInCapitalSubscriptionFeeReceivable	600,000
Noncontrolling Interest, Tax Payments on Behalf of Non-Controlling Interest	sgfy_NoncontrollingInterestTaxPaymentsOnBehalfOfNonControllingInterest	10,600,000
Additional Paid-in Capital [Member]
Stock Issued and Granted During Period, Value	sgfy_StockIssuedAndGrantedDuringPeriodValue	5,100,000
Stock Issued During Period, Value, Effect of Reorganization Transactions	sgfy_StockIssuedDuringPeriodValueEffectOfReorganizationTransactions	620,800,000
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	479,300,000
Stock Issued During Period, Value, Stock Options Exercised	us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised	2,700,000
Adjustments to Additional Paid in Capital, Contributions	sgfy_AdjustmentsToAdditionalPaidInCapitalContributions	26,000,000
Stock Issued During Period, Value, Conversion of Convertible Securities	us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	10,900,000
Adjustments to Additional Paid in Capital, Deferred Tax Adjustment	sgfy_AdjustmentsToAdditionalPaidInCapitalDeferredTaxAdjustment	6,300,000
Adjustments to Additional Paid in Capital, Tax Receivable Agreement Liability and Deferred Taxes Arising from LLC Interest Ownership Exchanges	sgfy_AdjustmentsToAdditionalPaidInCapitalTaxReceivableAgreementLiabilityAndDeferredTaxesArisingFromLLCInterestOwnershipExchanges	400,000
Adjustments to Additional Paid in Capital, Subscription Fee Receivable	sgfy_AdjustmentsToAdditionalPaidInCapitalSubscriptionFeeReceivable	600,000
Noncontrolling Interest [Member]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	us-gaap_ProfitLoss	(2,300,000)
Stock Issued and Granted During Period, Value	sgfy_StockIssuedAndGrantedDuringPeriodValue	3,700,000
Stock Issued During Period, Value, Effect of Reorganization Transactions	sgfy_StockIssuedDuringPeriodValueEffectOfReorganizationTransactions	254,900,000
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	125,300,000
Stock Issued During Period, Value, Conversion of Convertible Securities	us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	(10,900,000)
Noncontrolling Interest, Tax Payments on Behalf of Non-Controlling Interest	sgfy_NoncontrollingInterestTaxPaymentsOnBehalfOfNonControllingInterest	10,600,000
Retained Earnings [Member]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	us-gaap_ProfitLoss	(3,000,000)
Member Units [Member]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	us-gaap_ProfitLoss	(17,200,000)
Stock Issued During Period, Value, Effect of Reorganization Transactions	sgfy_StockIssuedDuringPeriodValueEffectOfReorganizationTransactions	(877,700,000)
Limited Liability Company (LLC) Members' Equity, Unit-based Payment Arrangement	us-gaap_LimitedLiabilityCompanyLLCMembersEquityUnitBasedCompensation	$ 900,000
Common Class B [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Effect of Reorganization Transactions	sgfy_StockIssuedDuringPeriodSharesEffectOfReorganizationTransactions	57,613,676
Stock Issued During Period, Value, Effect of Reorganization Transactions	sgfy_StockIssuedDuringPeriodValueEffectOfReorganizationTransactions	$ 600,000
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture	us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation	617,099
Common Class A [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Effect of Reorganization Transactions	sgfy_StockIssuedDuringPeriodSharesEffectOfReorganizationTransactions	140,758,464
Stock Issued During Period, Value, Effect of Reorganization Transactions	sgfy_StockIssuedDuringPeriodValueEffectOfReorganizationTransactions	$ 1,400,000
Stock Issued During Period, Shares, New Issues	us-gaap_StockIssuedDuringPeriodSharesNewIssues	27,025,000
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	$ 300,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised	824,045